WO2004066977A1 - Solid agent for dialysis and process for producing the same - Google Patents

Solid agent for dialysis and process for producing the same Download PDF

Info

Publication number
WO2004066977A1
WO2004066977A1 PCT/JP2004/000892 JP2004000892W WO2004066977A1 WO 2004066977 A1 WO2004066977 A1 WO 2004066977A1 JP 2004000892 W JP2004000892 W JP 2004000892W WO 2004066977 A1 WO2004066977 A1 WO 2004066977A1
Authority
WO
WIPO (PCT)
Prior art keywords
dialysis
solid
chloride
glucose
agent
Prior art date
Application number
PCT/JP2004/000892
Other languages
French (fr)
Japanese (ja)
Inventor
Yoshiaki Kawashima
Hirofumi Takeuchi
Ryoji Oura
Masaru Mori
Masao Nakashima
Shinichi Kadono
Original Assignee
Manac Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2003/007356 external-priority patent/WO2004067014A1/en
Application filed by Manac Inc. filed Critical Manac Inc.
Priority to JP2005504763A priority Critical patent/JP4603977B2/en
Publication of WO2004066977A1 publication Critical patent/WO2004066977A1/en
Priority to HK06109554A priority patent/HK1089089A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • A61M1/1666Apparatus for preparing dialysates by dissolving solids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Definitions

  • the present invention relates to a dialysis solid preparation for preparing bicarbonate dialysis solution used in dialysis therapy for patients with renal failure. More specifically, the surface of particles (mother particles) serving as mother nuclei during granulation is specified.
  • the present invention relates to a solid agent for dialysis, which is covered with a fused coating layer containing a salt, has excellent stability, uniform content, and excellent attrition resistance, and a method for producing the same. Background art
  • Dialysis therapy has been established as a treatment method for patients with renal failure, and is performed as a regular permanent treatment for the purpose of removing waste products and regulating electrolytes.
  • the dialysate used for dialysis therapy is made to have a composition similar to the normal serum electrolyte concentration, and in recent years, bicarbonate dialysate with less burden on the living body has been used.
  • Bicarbonate dialysis solution is generally a formulation containing sodium chloride and magnesium chloride and containing no sodium bicarbonate because sodium bicarbonate reacts with calcium chloride and magnesium chloride to precipitate carbonate.
  • a formulation containing sodium bicarbonate and containing no sodium chloride or magnesium chloride (agent B), which are dissolved, diluted and mixed immediately before use to prepare a bicarbonate dialysate.
  • “powder-powder type” solidifying agents obtained by pulverizing agent A have been developed and used.
  • This solid preparation is once dissolved in a stock solution of the same concentration as the “liquid-liquid type” concentrated stock solution using a dedicated dissolution apparatus at a medical site such as a hospital, and then further dissolved and diluted to a dialysate concentration.
  • a spray drying method, a wet granulation method, a dry granulation method and the like have been well known. Each method has its advantages and disadvantages and cannot be said to be satisfactory in terms of manufacturing method and quality.
  • Formulations by the spray-dry method are bulky, vary in moisture and particle size, and it is difficult to give a constant pH due to the volatilization of acid components.
  • Japanese Patent Application Laid-Open No. 2002-102703 discloses a method for producing a two-part solid baking soda dialysis preparation using a tumbling stirred fluidized bed granulator. There is a disadvantage that the coating layer is easily peeled off due to the collision of the granules. Furthermore, since the electrolyte component ⁇ glucose, which contains sodium chloride in part, must be dissolved in a considerable amount of water and then spray-dried, the unit energy consumption is significantly deteriorated.
  • the wet granulation method and the dry granulation method have the disadvantage that complicated steps such as pulverization and mixing are inevitable in order to maintain uniformity, and are liable to be contaminated by foreign substances from the equipment used or from outside.
  • each electrolyte compound is mixed and heated (73 ° C) in the presence of sodium acetate and water, and then glucose is added, mixed with acetic acid, and a plurality of sodium chloride particles pass through the coating layer.
  • a method for producing a granular or fine granular agent A for perfusion of an artificial kidney for dialysis of bicarbonate composed of combined granules is disclosed (see Japanese Patent No. 2769592).
  • the granulation is performed at 60 ° C, a core layer containing at least one member selected from the group consisting of sodium chloride and potassium chloride as a main component, a double salt formed by a reaction between sodium acetate and calcium chloride, and the like.
  • a solid dialysis agent having a double-layered structure with an electrolyte composition and a double salt layer containing a pH adjusting agent (see Japanese Patent No. 2987488).
  • Patent No. 27695992 Patent No. 27984888 and Japanese Patent Application Laid-Open No. 2002-102337, 60 ° C.
  • the coating layer of the preparation manufactured by such a manufacturing method is a layer in which fine particles are adhered and laminated via a binder, and are easily affected by external factors, so that glucose is decomposed and colored. It has the drawback that it can proceed more easily over time, and has a major problem of lack of storage stability.
  • the coating layer is easily peeled off during transportation, so that fine powder is produced. This is combined with the generation of static electricity, causing various problems.
  • static electricity is generated at the same time as dust is generated at the time of product filling, and fine powder adheres to the sealing part of the packaging bag and the strength of the seal decreases, and in the worst case, the bag may be broken.
  • dust containing acetic acid is scattered during the preparation of the dialysate, which deteriorates the working environment, and that the solidifying agent tends to remain in the bag due to static electricity.
  • foreign matter adheres to the outside of the packaging material due to the generation of static electricity, which also causes foreign matter to enter during melting, and there is a strong need for improvement.
  • An object of the present invention is to provide a solid solution for dialysis comprising an electrolyte, pudose, and a pH adjuster necessary for preparing a bicarbonate dialysis solution, in which glucose is stably present both in the production stage and during storage. Offers storage stability, uniform content, excellent abrasion resistance, and excellent solubility, no danger of decomposition and coloration, extremely low dusting, and prevention of static electricity. To do. Summary of the invention
  • the present inventors have conducted intensive studies to achieve the above object, and as a result, In a system where calcium chloride and sodium acetate are present, in the presence of a small amount of water, if the stirring temperature and the shearing force are set within the specified range and stirred and mixed for a specified time or longer, complicated granulation operations and special equipment must be used. Instead, a fused coating layer was formed on the base particles, and the above-mentioned problem was achieved.
  • the present invention (1) relates to a thin film X-ray diffraction method for an electrolyte composition comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, a pH adjusting agent, and a solid dialysis agent comprising glucose.
  • a thin film X-ray diffraction method for an electrolyte composition comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, a pH adjusting agent, and a solid dialysis agent comprising glucose.
  • the present invention (2) is the solidifying agent according to the above-mentioned invention (1), which is in the form of granules and Z or fine granules.
  • the present invention (3) is the solid preparation for dialysis according to the above-mentioned invention (1) or (2), wherein the salt is a reaction product of glucose, calcium chloride and sodium acetate.
  • the present invention (4) is the solid agent for dialysis according to any one of the inventions (1) to (3), wherein the coating layer is in a fused state.
  • the present invention (5) is a solid agent for bicarbonate dialysis comprising the solid agent for dialysis according to any one of the inventions (1) to (4) and a solid agent containing sodium bicarbonate.
  • the present invention (6) has a moisture permeability (40 ° C., 90% RH) of 2.0 g / m 2 -24 hr or less, and is housed in a moisture-proof packaging material having a laminated structure having a back electrode effect.
  • the present invention (7) provides an electrolyte composition comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and sodium acetate, a pH adjuster, and a solid preparation for dialysis produced from bead bran.
  • a powder and Z or granules containing one or more raw material components of the solid agent 0.1 to 2 weight based on the weight of the powder and / or granules. /.
  • the manufacturing method is characterized in that:
  • shearing force refers to a value calculated by the following equation:
  • the present invention (8) is the production method according to the above-mentioned invention (7), wherein the aqueous solution has a viscosity of 0.001 to 2 Pa's.
  • the present invention is the production method according to the above invention (7) or (8), wherein the aqueous solution is an aqueous solution containing glucose and magnesium chloride.
  • the present invention provides the dialysis solid preparation according to any one of the inventions (7) to (9), wherein the dialysis solid preparation is any one of the inventions (1) to (6).
  • the dialysis solid preparation is any one of the inventions (1) to (6).
  • FIG. 1 is an image diagram showing a cross-sectional state of a solidifying agent according to the present invention of a type in which particles cannot be recognized on the surface or inside at a glance.
  • 1 indicates a coating layer and 2 indicates a mother particle.
  • FIG. 2 is an image diagram showing a cross-sectional state of a solid agent according to the present invention of a type in which particles can be confirmed on the surface and inside.
  • A indicates particles
  • B indicates a fusion layer.
  • FIG. 3 is an image diagram showing a state of a cross section of a conventional solid agent in which countless particles appear to be deposited.
  • 1 ' indicates a sedimentary layer
  • 2' indicates a base particle
  • C indicates a particle.
  • FIG. 4 is an image diagram showing the significance of “fused” in the present invention.
  • FIG. 5 is an image diagram showing the significance of “stacking” in the conventional technology.
  • D indicates a binder.
  • FIG. 6 is a digital micrograph of the solid preparation for dialysis obtained in Example 1 (digital photograph).
  • FIG. 7 is an electron micrograph of the solid preparation for dialysis obtained in Example 1 (digital photograph).
  • FIG. 8 shows an elemental analysis result (energy dispersive X-ray analyzer (EDX)) of the base particles of the solid preparation for dialysis obtained in Example 1.
  • EDX energy dispersive X-ray analyzer
  • FIG. 9 shows the results of elemental analysis (energy dispersive X-ray analyzer (EDX)) of the coating layer of the solid agent for dialysis obtained in Example 1.
  • EDX energy dispersive X-ray analyzer
  • FIG. 10 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Example 1.
  • FIG. 11 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Example 2.
  • FIG. 12 is an electron micrograph of the dialysis solid obtained in Comparative Example 1 (digital photograph).
  • FIG. 13 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Comparative Example 1.
  • FIG. 14 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Comparative Example 2.
  • the solid agent for dialysis according to the present invention is essentially the same in composition as conventional ones, and includes various electrolytes (sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate), pH adjusters. And grape bran.
  • the pH adjuster is not particularly limited as long as it is pharmacologically acceptable. Examples thereof include liquid acids such as acetic acid and hydrochloric acid, lactic acid, citric acid, malic acid, and diacid. Examples thereof include solid acids such as sodium acetate, and these may be used alone or in combination of two or more. Preferably, acetic acid and sodium diacetate.
  • a feature of the solid agent for dialysis according to the present invention is that the base particles are covered with a coating layer containing a specific salt.
  • the coating layer according to the present invention will be described.
  • the salt was a reaction product of glucose, calcium chloride, and sodium acetate.
  • the solid agent for dialysis according to the present invention uses most of calcium chloride in the stirring granulation process. Is presumed to be specifically reacted with glucose and sodium acetate and contained in the coating layer as the salt, so that the storage stability is extremely good. In addition, it has been confirmed that the solid agent for dialysis containing the salt has a predetermined electrolyte ion concentration and a predetermined glucose concentration when dissolved in predetermined water.
  • the coating layer according to the present invention may contain components other than the salt.
  • sodium chloride, potassium chloride, magnesium chloride, sodium acetate, glucose and / or ⁇ ⁇ It may contain a regulator.
  • the coating layer according to the present invention is in a fused state.
  • fused means ⁇ as when a melt is solidified, and may be referred to as "agglomerated”. It should be noted that the appearance is a fused state, and does not mean that the material is actually heated to a melting point or more to be melted. It can also be described as being amorphous (this does not mean that it is composed of amorphous but means that the appearance appears to be amorphous). Not all of them need to be fused together, and they may be in a state of containing particles on the surface or inside.
  • the conventional coating layer of the solid agent for dialysis has a structure in which innumerable particles C are deposited on the base particles 2 ′.
  • the particles C and the particles C have a force of binding via the binder D, that is, a structure simply riding on the particles.
  • the “fused coating layer” according to the present invention as shown in FIG. Have. However, it is sufficient if the external appearance is such that most of the particles are integrated, and even if particles ⁇ that are not in a fused state exist on the surface or inside of the coating layer 1 as shown in FIGS. Invention "Fused coating layer".
  • the base particles according to the present invention are not particularly limited, and are composed of a raw material component of a solid agent.
  • base particles composed of sodium salt and mother particles composed of other components for example, potassium chloride, sodium acetate, and glucose
  • the base particles of most of the particles are made of sodium chloride
  • the base particles of the remaining particles are made of other raw material components. .
  • the salt is contained in the coating layer, for example, even if sodium chloride is contained in the coating layer, glucose is contained in the mother particles, and solid
  • the raw material components and reaction products of the agent may be contained in either the base particles or the coating layer, or may be contained in both.
  • magnesium chloride is preferably contained in the coating layer.
  • the solid agent for dialysis according to the present invention is typically a granular and / or fine granulated product.
  • the average particle size is preferably about 220 to 800 m, and the thickness of the coating layer is preferably 10 to 70 ⁇ .
  • the granulated product may be a single particle in which a coating layer is formed on the surface of a base particle, or a product in which a plurality of coated base particles are bonded via a coating layer. Good.
  • the shape of a single particle of the granulated material is mainly a slightly rounded cube.
  • what is bound via the coating layer is a shape in which several coated cubic particles are bound.
  • the method for producing a solid preparation for diffusion according to the present invention comprises the steps of: providing a powder and / or granules containing at least one raw material component of the solid preparation; 22% by weight of water in the form of purified water or an aqueous solution containing at least one raw material component of the solid agent (wherein the mixture contains at least pudose sugar, calcium chloride and sodium acetate), A step of stirring and granulating the mixture at a shearing force of not less than 0.003 kW / kg per 1 kg of the mixture at 50 ° C or less for 1 minute or more. Details will be described below.
  • the “powder and Z or granule” according to the present invention comprises at least one raw material component (sodium chloride, potassium chloride, sodium acetate, calcium chloride, magnesium chloride, glucose, and a pH adjuster) of the solid agent. One or more selected from raw material groups).
  • the powders and / or granules are basically in dry form, optionally impregnated with a liquid pH adjuster.
  • the particle size of each particle is not particularly limited, but the difference between the particle sizes is as small as possible.
  • the average particle diameter is preferably about 200 to 600 ⁇ , and the difference between the average particle diameters of the respective particles is The combination is preferably such that the average particle size of the particles is within 30%, and the particle size of calcium chloride is preferably not more than 300 m in order to promote the reaction between glucose and sodium acetate.
  • the “aqueous solution” of the “aqueous solution containing one or more raw material components of purified water or the solid agent” according to the present invention will be described.
  • this aqueous solution is referred to as “the aqueous solution” unless otherwise specified.
  • the solute of the aqueous solution is not particularly limited, and is one selected from the group consisting of sodium chloride salt, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, a pH adjuster, and glucose, which are raw material components of the solid agent. That is all. It is not necessary that all of the components are dissolved, and some of them may be in a solid state.
  • a preferred embodiment is an aqueous solution containing butdu sugar and magnesium chloride.
  • a stronger coating layer can be formed.
  • the glucose concentration in this aqueous solution is preferably 10 to 70% by weight, more preferably 20 to 60% by weight, and the concentration of magnesium chloride (hexahydrate) is preferably There are 10-70 weight 0 /. More preferably, it is 25 to 60% by weight.
  • the pudose is stably maintained and both the concentration is much higher than the solubility of a single substance.
  • this aqueous solution may contain components other than these, for example, an embodiment further including an electrolyte such as calcium chloride.
  • This aqueous solution can be prepared simply by dissolving grape bran in an aqueous solution of magnesium chloride.
  • the aqueous solution preferably has a viscosity of 0.01 to 2 Pa's, more preferably 0.01 to 1.5 Pa's, and still more preferably 0.01 to 15 Pa's. 1 Pa 's. The viscosity here indicates a value measured by a B-type viscometer.
  • a mixture consisting of “powder and powder or granules” and “purified water or an aqueous solution containing at least one raw material component of the solidifying agent” contains at least glucose, calcium chloride and sodium acetate.
  • these components may be contained only in the powder and Z or granules, may be contained only in the aqueous solution, or may be contained in both.
  • Preferable examples of the combination of "powder and / or granule” and “aqueous solution” include “powder and / or granule” .1 Includes sodium chloride, potassium chloride, sodium acetate, pudose sugar, and optionally calcium chloride. "Aqueous solution” contains glucose and magnesium chloride, and optionally contains calcium chloride.All raw materials of the solid preparation are defined as “powder and / or granules" + “aqueous solution”. It is not necessary to use it, and part of the raw material may be added in the subsequent steps. For example, with respect to pH adjusters, they can be added in advance in “powder and Z or granules”, added during granulation, added before drying, or added during drying. May also be added after drying.
  • the amount of water in the “purified water or the aqueous solution containing at least one raw material component of the solid agent” to be added to the system is from 0.1 to the total amount of the “powder and / or granules” present in the system. It is preferably 2.0% by weight, more preferably 0.2 to 1.4% by weight.
  • the amount of water added to the system does not include water of crystallization in the raw materials.
  • the time from the addition of purified water or the aqueous solution to the completion of granulation is as follows: the time required for the reaction of the salt, the uniformity of the content of the formed granules, and the smoothness (even though the water content is about 2% by weight) Considering that the fluidity is good, the moisture resistance is high, and free water that causes adhesion and coagulation hardly forms on the surface of the coating layer), it is preferable that the time is 1 minute or more. It is preferably at least 3 minutes, more preferably at least 10 minutes. Also, from the viewpoint of preventing fracture, the time is preferably 30 minutes or less.
  • the shearing force applied during stirring will be described.
  • the stirring granulation according to the present invention When a stirring-type mixing granulator is used, the stirring granulation according to the present invention At the time of granulation, a shear force is applied to the mixture between the stirring blade and the inner wall of the device due to the rotation of the stirring blade.
  • the magnitude of this shearing force was calculated by the above equation using the load of the stirring motor of the apparatus (motor current value), and the value was defined as the shearing force applied per kg of the mixture.
  • the required shearing force is not less than 0.003 kWZkg, preferably not less than 0.01 kW / kg, and more preferably not less than 0.05 kW / kg.
  • the upper limit is preferably 0.1 kW / kg or less from the viewpoint of increasing the internal temperature and preventing crushing.
  • the temperature at which stirring granulation is performed is sufficient at a temperature around room temperature, and granulation can be performed at a temperature that is extremely effective in preventing decomposition of pudose. That is, it is essential that the temperature at which the granulation of the present invention is carried out is not more than 50 ° C. from the viewpoint of salt formation.
  • the lower limit is not particularly limited, but is preferably at least o ° c. In addition, more preferably
  • the temperature of the purified water or the aqueous solution (before addition) is preferably 15 to 50 ° C.
  • a stirring-type mixing granulation apparatus used in the stirring-granulation step a high-speed stirring-type granulation apparatus is suitable. The operating conditions are sufficiently achieved within the range of general conditions for granulation.
  • the steps after the granulation step, the equipment to be used, and the operating conditions are not particularly limited, but the obtained granules are dried, and if necessary, before or after drying, a pH adjuster is added and mixed, and the granules are granulated. A granulated and Z- or fine-grained solid for dialysis is obtained.
  • the bicarbonate dialysate can be adjusted to, for example, the following concentrations:
  • the packaging material for the solid preparation for dialysis obtained in this manner a material having good moisture-proof performance and having a back electrode effect is preferable.
  • a film was made by kneading an antistatic agent into a resin and then processed into a packaging material having an antistatic function.However, foreign materials mixed into the product due to the bleeding phenomenon from the resin were used. Inconvenience was seen.
  • the antistatic agent is contained in the adhesive used for bonding the film, it does not penetrate the film, and the bleeding phenomenon does not occur.
  • the antistatic agent is contained in the adhesive on the back side of the film surface in contact with the solid agent for dialysis, and is a laminated film having an antistatic function up to the back surface. That is, moisture permeability (40.C, 90% RH) 2. Og / m 2 - 24h r following film, for example, using a silica-deposited film, antistatic ⁇ adhesive, for example Bonn dip (Konishi Co., Ltd.) It is preferable to fill and package a dialysis solid in a packaging material having a back electrode effect, which is processed using a laminated film adhered and used. Examples of the configuration of a laminated film having such a laminated structure include:
  • the laminating film can be easily produced by a known method. As an example of the production method, measure the required amount of the antistatic adhesive, dilute it with a solvent if necessary, mix the liquid evenly, and use a coater such as a gravure coater or reverse coater. Then, it is applied to the above-mentioned film, dried with hot air, and completely cured. The obtained laminated film can be processed into a packaging material by heat sealing. Example Hereinafter, the present invention will be described more specifically with reference to Examples.
  • An aqueous solution was prepared by dissolving 26.1 g of potassium chloride, 17.8 g of magnesium chloride, 38.6 g of calcium chloride and 86.1 g of sodium acetate in 400 g of purified water.
  • Sodium chloride 1063. 6 g and Pudou sugars 175. Og were charged into a tumbling fluidized bed granulator, the air supply temperature 80 ° C, the rotor rotational speed 15 Orpm, under the conditions of supply air volume 0. 7 m 3 / min
  • the aqueous solution was sprayed and dried at the same time to obtain a granulated product. After sizing, 21. Og of acetic acid was added to the obtained granules and mixed to obtain a preparation.
  • 1066.6 g of sodium chloride, 26.lg of potassium chloride, 17.8 g of magnesium chloride, 38.6 g of calcium chloride, 86.lg of sodium acetate, and 175.0 g of glucose are powder-framed to about 75 m, mixed, and compressed. Granulation was performed using a rotary granulator. After sizing, acetic acid was added to the obtained granules and mixed to obtain a preparation.
  • FIG. 6 shows a micrograph (manufactured by Keyence Corporation) of the preparation obtained in Example 1. From this figure, it can be seen that the present preparation obtained in Example 1 is present as a single particle, or as an aggregate in which a plurality of base particles are bonded via a coating layer.
  • Fig. 7 shows the structure of the coating layer of the same preparation using a digitally operated electron microscope (manufactured by Hitachi, Ltd.). From this figure, it can be confirmed that the coating layer of the same preparation has an appearance as if fused. 8 and 9 show the results of elemental analysis (EDX) of the mother particles and the coating layer, respectively. From FIG. 8, it was confirmed that sodium chloride was present as mother particles. In addition, elemental analysis of the other mother particles confirmed that potassium chloride, sodium acetate and grape bran were present as mother particles.
  • EDX elemental analysis
  • a sample preparation method will be described. Approximately 0.5 g of each sample was taken from each preparation and compression molded into a disk of uniform thickness using a tableting machine. The tableting pressure was such that the base particles of the drug product did not break, and the sample size was about 2 Omm in diameter and about 2 mm in thickness.
  • Example 2 Six samples were randomly sampled from the preparation obtained in Example 1, and 8.5 Og of sample was dissolved in water to make exactly 20 Oml for each sample, and this was diluted 50-fold to obtain Na + , K + , The concentration of each of the electrolytes Mg 2+ , Ca 2+ , C 1— and CH 3 CO— was measured by an ion chromatograph manufactured by Tosoh Corporation. For glucose, 8.50 g of the sample was dissolved in water to make exactly 100 ml, and the glucose was measured by liquid chromatography manufactured by Tosoh Corporation. Table 1 shows the measurement results. table 1
  • Example 2 The concentration of each component of the preparation obtained in Example 2 was carried out in the same manner as in Example 1, and the results are shown in Table 2.
  • Table 4 shows the results of the consolidation test. The sample was opened after applying a load for a predetermined period of time, lightly sieved with a 16-mesh sieve, and the amount of the unsieved residue was measured. The sieving residue is represented by ⁇ when the content is within 10% by weight, the ⁇ when the content is 10 to 50% by weight, and X when the remaining amount is more than 10%. Table 4
  • composition of each component in the preparation covered with the coating agent in such a fused state is a preparation having a composition very close to the theoretical value as shown in Tables 1 and 2, and the solid preparation for dialysis of the present invention is It can be seen that the content uniformity of each component is sufficient.
  • the results of the stability test are excellent as shown in Table 3, and as shown in Table 4, the results of the caking test are good and the product can be stored for a long period of time.
  • the dissolution rate is high, and as shown in Table 6, the formulation is easy to handle due to extremely low dusting. The invention's effect
  • the solid agent according to the present invention is a granulated product in which the coating layer in a state of being strongly fused is coated with the mother particles, and other examples include electrolytes such as sodium chloride and chlorine-containing rim, and aqueous solutions of glucose.
  • electrolytes such as sodium chloride and chlorine-containing rim
  • aqueous solutions of glucose Compared to a film manufactured by spray granulation method or the like as shown in Fig. 3 or a film as shown in Fig. 3, the surface is denser, so it is less susceptible to external factors and has excellent long-term storage stability. It is said that the workability of the dissolution operation at the medical site is much better than before because it has good fluidity, good abrasion resistance and good consolidation resistance, hardly generates dust, and has a high dissolution rate. It works.
  • the method for producing a solid preparation according to the present invention it is not necessary to heat for a long time as compared with the conventional method, so that danger of glucose being decomposed and colored during granulation can be avoided, and A solid preparation having excellent content uniformity can be obtained without requiring complicated operations such as grinding and sieving.
  • the mixture that has been in the form of wet particles becomes a smooth, apparently dry granule, Z or fine granule in a short time at around room temperature, and is easily formed. The granulation is completed. Therefore, handling such as transfer, drying, and mixing, which is the next step, becomes extremely easy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)

Abstract

A solid agent for dialysis comprising an electrolyte, glucose and a pH adjusting agent required for the preparation of a bicarbonate dialyzing fluid, which solid agent for dialysis ensures stable presence of glucose in the stage of not only production but also storage, being free from the danger of decomposition and coloring and excels in storage stability, content uniformity and abrasion resistance, realizing extremely high workability on medical spots. In particular, a solid agent for dialysis comprising an electrolyte composition (the electrolyte composition composed of sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate), a pH adjusting agent and glucose characterized in that base particles are covered by a coating layer comprising a salt having, in thin-film X-ray diffraction, specified peaks at 2θ = 21.3 to 21.5° and 2θ = 27.6 to 27.8° (CuKα: λ = 1.54058 Å, and incident angle θ = 1°).

Description

明 細 書  Specification
透析用固形剤及びその製造方法 技術分野 Technical Field
本発明は、 腎不全患者の透析療法に使用される重炭酸透析液調製用の透析用固 形剤に関し、 詳しくは、 造粒の際に母核となる粒子 (母粒子) の表面が、 特定の 塩を含む融着状の被覆層で覆われた、 安定性及び含量均一性更には耐摩損性に優 れた透析用固形剤及びその製造方法に関する。 背景技術  The present invention relates to a dialysis solid preparation for preparing bicarbonate dialysis solution used in dialysis therapy for patients with renal failure. More specifically, the surface of particles (mother particles) serving as mother nuclei during granulation is specified. The present invention relates to a solid agent for dialysis, which is covered with a fused coating layer containing a salt, has excellent stability, uniform content, and excellent attrition resistance, and a method for producing the same. Background art
透析療法は、 腎不全患者の治療方法として確立されており、 老廃物の除去、 電 解質の調節等を目的に定期的な永続的治療として行われている。 透析療法に用い られる透析液は、 正常な血清電解質濃度に類似した組成を持つように作成されて おり、 近年では生体に負担の少ない重炭酸透析剤が用いられている。 重炭酸透析 液は、 重炭酸ナトリゥムが塩化カルシウムや塩化マグネシウムと反応して炭酸塩 の沈殿を生じるため、 一般的に塩ィ匕カルシゥムゃ塩化マグネシゥムを含み重炭酸 ナトリウムを含まない製剤 (A剤) と重炭酸ナトリウムを含み塩ィ匕カルシウムや 塩化マグネシウムを含まない製剤 (B剤) の 2剤に分けられており、 使用直前に それぞれが溶解、 希釈混合されて重炭酸透析液が調製される。  Dialysis therapy has been established as a treatment method for patients with renal failure, and is performed as a regular permanent treatment for the purpose of removing waste products and regulating electrolytes. The dialysate used for dialysis therapy is made to have a composition similar to the normal serum electrolyte concentration, and in recent years, bicarbonate dialysate with less burden on the living body has been used. Bicarbonate dialysis solution is generally a formulation containing sodium chloride and magnesium chloride and containing no sodium bicarbonate because sodium bicarbonate reacts with calcium chloride and magnesium chloride to precipitate carbonate. And a formulation containing sodium bicarbonate and containing no sodium chloride or magnesium chloride (agent B), which are dissolved, diluted and mixed immediately before use to prepare a bicarbonate dialysate.
現在、 血液透析で使用されている主な製剤の形式は、 A濃厚原液 + B濃厚原液 の 「液液タイプ」、 A濃厚原液 + B粉末剤 (重炭酸ナトリウム) の 「液粉タイプ」、 A粉末剤 + B粉末剤の 「粉粉タイプ」 の 3種類がある。 「液液タイプ」、 「液粉タイ プ」 のうち濃厚原液の製剤は、 通常ポリエチレン製の容器に 1 O kg前後の濃厚液 が充填されているため容器の嵩が大きく重量があり、 輸送、 搬入、 保管スペース、 取り扱い方法、 使用済み容器の廃棄等について種々の課題を抱えている。  Currently, the main types of preparations used in hemodialysis are "Liquid-liquid type" of A concentrate + B concentrate, "Liquid powder type" of A concentrate + B powder (sodium bicarbonate), and A There are three types: powder + B powder. Among the “liquid-liquid type” and “liquid-powder type”, concentrate concentrates are usually bulky and heavy because polyethylene containers are filled with around 1 kg of concentrated liquid. There are various issues regarding loading, storage space, handling methods, and disposal of used containers.
これらの問題を解決するために、 近年、 A剤を粉末化した 「粉粉タイプ」 の固 形剤が開発されて使用されつつある。 この固形剤は、 病院などの医療現場で専用 の溶解装置を使用して 「液液タイプ」 の濃厚原液と同程度の濃度の原液に一旦溶 解され、 その後更に溶解、 希釈され透析液濃度に調製される。 このような固形剤の製剤化方法としては、 従来よりスプレードライ法、 湿式造 粒法、 乾式造粒法などがよく知られている。 いずれの方法も一長一短があり、 製 造方法や品質の面で満足すべきものとは言えない。 スプレードライ法による製剤 は、 嵩高く、 水分や粒度にばらつきがあり、 酸成分が揮散するため一定の p Hを 与えるのが難しい。 特開 2 0 0 2— 1 0 2 3 3 7号公報では、 転動撹拌流動層造 粒装置を用いた 2剤型固形重曹透析用製剤の製造方法が開示されており、 この方 法は流動している造粒物同士の衝突により被覆層がはがれやすレヽという欠点があ る。 更に、 一部塩化ナトリウムを含む電解質成分ゃブドウ糖を相当量の水に溶解 した上に、.嘖霧乾燥をしなければならないために、 エネルギー原単位を著しく悪 化させている。 湿式造粒法や乾式造粒法は、 均一性を保持するために、 粉碎、 混 合等の煩雑な工程が避けられず、 使用設備や外部からの異物混入により汚染され やすいという欠点がある。 In order to solve these problems, in recent years, “powder-powder type” solidifying agents obtained by pulverizing agent A have been developed and used. This solid preparation is once dissolved in a stock solution of the same concentration as the “liquid-liquid type” concentrated stock solution using a dedicated dissolution apparatus at a medical site such as a hospital, and then further dissolved and diluted to a dialysate concentration. Be prepared. As a method for formulating such a solid preparation, a spray drying method, a wet granulation method, a dry granulation method and the like have been well known. Each method has its advantages and disadvantages and cannot be said to be satisfactory in terms of manufacturing method and quality. Formulations by the spray-dry method are bulky, vary in moisture and particle size, and it is difficult to give a constant pH due to the volatilization of acid components. Japanese Patent Application Laid-Open No. 2002-102703 discloses a method for producing a two-part solid baking soda dialysis preparation using a tumbling stirred fluidized bed granulator. There is a disadvantage that the coating layer is easily peeled off due to the collision of the granules. Furthermore, since the electrolyte component ゃ glucose, which contains sodium chloride in part, must be dissolved in a considerable amount of water and then spray-dried, the unit energy consumption is significantly deteriorated. The wet granulation method and the dry granulation method have the disadvantage that complicated steps such as pulverization and mixing are inevitable in order to maintain uniformity, and are liable to be contaminated by foreign substances from the equipment used or from outside.
そこで、 このような点に着目した、 粉碎等の煩雑な工程が不要な製造方法で、 嵩比重、安息角及び溶解速度が良好でコンパクトな固形製剤の提案がなされている。 例えば、 各電解質化合物を酢酸ナトリウム、 水の存在下で混合、 加熱 (7 3 °C) し、 その後にブドウ糖を加え、 酢酸と混合して、 複数個の塩化ナトリウム粒子が 該コーティング層を介して結合した造粒物からなる顆粒状乃至は細粒状の重炭酸 透析用人工腎臓灌流用の A剤の製造方法が示されている (特許第 2 7 6 9 5 9 2号公報参照)。 また、 造粒を 6 0 °Cで行い、 塩化ナトリゥム及び塩 化カリゥムからなる群から選ばれる少なくとも 1種を主成分として含む核層と、 酢酸ナトリゥムと塩化カルシウムの反応により生成した複塩、 他の電解質組成物 及び p H調整剤を含む複塩層との二層構造を有する固形透析用剤が示されている (特許第 2 9 8 7 4 8 8号公報参照)。  Therefore, attention has been paid to such a point, and a compact solid preparation having a good bulk specific gravity, an angle of repose, and a dissolution rate has been proposed by a manufacturing method which does not require complicated steps such as pulverization. For example, each electrolyte compound is mixed and heated (73 ° C) in the presence of sodium acetate and water, and then glucose is added, mixed with acetic acid, and a plurality of sodium chloride particles pass through the coating layer. A method for producing a granular or fine granular agent A for perfusion of an artificial kidney for dialysis of bicarbonate composed of combined granules is disclosed (see Japanese Patent No. 2769592). The granulation is performed at 60 ° C, a core layer containing at least one member selected from the group consisting of sodium chloride and potassium chloride as a main component, a double salt formed by a reaction between sodium acetate and calcium chloride, and the like. There is disclosed a solid dialysis agent having a double-layered structure with an electrolyte composition and a double salt layer containing a pH adjusting agent (see Japanese Patent No. 2987488).
ところが、 この製造方法には大きな問題が含まれている。 すなわち、 特許第 2 7 6 9 5 9 2号公報では、 塩化ナトリウム、 塩化力リウム、 塩化マグネシウム、 塩化カルシウムと純水を混合、 攪拌、 加熱し酢酸ナトリウムを添カ卩し加熱混合を 続けた場合、 特許第 2 9 8 7 4 8 8号公報では、 塩化ナトリゥム、 塩化力リゥム、 塩化マグネシウム、 酢酸ナトリウムと純水を混合、 攪拌、 加熱し塩化カルシウム を添カ卩し加熱混合を続けた場合、 いずれの場合においても、 内容物に特異な粘り が生じ、 粘度が著しく増大し攪拌が困難になる。 通常の攪拌装置では製造が困難 であり、 攪拌能力の極めて大きな設備が必要となり、 設備が特殊化、 大型化する ために製造費用が著しく増加するという問題があり、 安価に、 容易に製造できる 製剤が求められている。 However, this manufacturing method has major problems. That is, in Japanese Patent No. 27695992, sodium chloride, potassium chloride, magnesium chloride, calcium chloride and pure water are mixed, stirred, heated, and sodium acetate is added, and heating and mixing are continued. According to Japanese Patent No. 298774888, sodium chloride, chloride chloride, magnesium chloride, sodium acetate and pure water are mixed, stirred, heated, and calcium chloride is added, and heating and mixing are continued. In any case, the inherent stickiness of the contents And the viscosity increases remarkably, making it difficult to stir. It is difficult to manufacture with a normal stirrer, and equipment with extremely large stirring capacity is required. Is required.
また、 特許第 2 7 6 9 5 9 2号公報、 特許第 2 9 8 7 4 8 8号公報及び特開 2 0 0 2 - 1 0 2 3 3 7号公報のいずれにおいても、 6 0 °C以上で長時間加熱す る必要があり、 造粒中にブドウ糖が分解、 着色しているおそれが強く、 上記方法 により得られる透析用製剤は含量均一性に劣る恐れがある。 更に、 このような製 造方法によって製造された製剤の被覆層は、 微細な粒子が結合剤を介して付着、 積層されたもので、 外部要因の影響を受けやすくなるためブドウ糖の分解、 着色 が経時的により一層進みやすレ、という欠点を有し、 保存安定性に欠けるという大 きな問題を抱えている。  Further, in each of Patent No. 27695992, Patent No. 27984888 and Japanese Patent Application Laid-Open No. 2002-102337, 60 ° C. As described above, it is necessary to heat for a long time, there is a strong possibility that glucose is decomposed and colored during granulation, and the dialysis preparation obtained by the above method may have poor content uniformity. Furthermore, the coating layer of the preparation manufactured by such a manufacturing method is a layer in which fine particles are adhered and laminated via a binder, and are easily affected by external factors, so that glucose is decomposed and colored. It has the drawback that it can proceed more easily over time, and has a major problem of lack of storage stability.
更には、 被覆層の構造上の特性より、 輸送時に被覆層が剥離しやすく微粉が生 じゃすい製剤となっており、 静電気の発生と相まって種々の問題が発生している。 例えば、 製造工程では製品充填時に発塵と同時に静電気が発生し、 包装袋のシー ル部に微粉が付着してシール強度が低下するという不都合が見られ、 最悪の場合 破袋することも考えられる。 一方、 透析現場の取り扱い時においては、 透析液調 製時に酢酸を含んだ粉塵が飛散し作業環境が悪くなるとともに、 静電気により固 形剤が袋の中に残りやすいという問題点が生じている。 更に、 包材外側にも静電 気の発生により異物が付着し、 溶解時の異物混入の原因にもなつており、 改善が 強く求められている。  Furthermore, due to the structural characteristics of the coating layer, the coating layer is easily peeled off during transportation, so that fine powder is produced. This is combined with the generation of static electricity, causing various problems. For example, in the manufacturing process, static electricity is generated at the same time as dust is generated at the time of product filling, and fine powder adheres to the sealing part of the packaging bag and the strength of the seal decreases, and in the worst case, the bag may be broken. . On the other hand, when handling dialysis, there is a problem in that dust containing acetic acid is scattered during the preparation of the dialysate, which deteriorates the working environment, and that the solidifying agent tends to remain in the bag due to static electricity. In addition, foreign matter adheres to the outside of the packaging material due to the generation of static electricity, which also causes foreign matter to enter during melting, and there is a strong need for improvement.
本発明の目的は、 重炭酸透析液を調製するために必要な電解質、 プドウ糖及び p H調整剤からなる透析用固形剤において、 製造段階においても、 保存時におい てもブドウ糖が安定に存在し、 分解や着色の恐れがなく、 保存安定性、 含量均一 性、 耐摩損性、 溶解性に優れ、 粉立ちも極めて少なく、 静電気の発生を防止した 作業性の極めて良好な透析用固形剤を提供する事にある。 発明の要旨  An object of the present invention is to provide a solid solution for dialysis comprising an electrolyte, pudose, and a pH adjuster necessary for preparing a bicarbonate dialysis solution, in which glucose is stably present both in the production stage and during storage. Offers storage stability, uniform content, excellent abrasion resistance, and excellent solubility, no danger of decomposition and coloration, extremely low dusting, and prevention of static electricity. To do. Summary of the invention
本発明者らは、 上記の目的を達成するため鋭意研究を重ねた結果、 ブドウ糠と 塩化カルシウムと酢酸ナトリゥムとが存在する系において、 少量の水の存在下で、 攪拌温度と剪断力を所定範囲に設定し所定時間以上攪拌混合すると、 複雑な造粒 操作や特殊な設備を用いることなく、 母粒子に融着状の被覆層が形成され、 上記 の課題が達成される事を見出した。 The present inventors have conducted intensive studies to achieve the above object, and as a result, In a system where calcium chloride and sodium acetate are present, in the presence of a small amount of water, if the stirring temperature and the shearing force are set within the specified range and stirred and mixed for a specified time or longer, complicated granulation operations and special equipment must be used. Instead, a fused coating layer was formed on the base particles, and the above-mentioned problem was achieved.
即ち、 本発明 (1) は、 塩化ナトリウム、 塩化カリウム、 塩化カルシウム、 塩 化マグネシウム及び酢酸ナトリゥムからなる電解質組成物、 p H調整剤並びにブ ドウ糖からなる透析用固形剤において、 薄膜 X線回折で 2 0 = 2 1. 3〜 21. 5° 及び 20 =27. 6〜27. 8° (CuKo: ; ;L = l. 54058 A、 入射角 Θ ^ 1° :)に特定のピークを有する塩を含む被覆層で母粒子が覆われている ことを特徴とする透析用固形剤である。  That is, the present invention (1) relates to a thin film X-ray diffraction method for an electrolyte composition comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, a pH adjusting agent, and a solid dialysis agent comprising glucose. With specific peaks at 20 = 21.3-21.5 ° and 20 = 27.6-27.8 ° (CuKo:;; L = l. 54058 A, incident angle Θ ^ 1 ° :) A solid preparation for dialysis, wherein the base particles are covered with a coating layer containing a salt.
また、 本発明 (2) は、 顆粒状及ぴ Z又は細粒状である、 前記発明 (1) の透 析用固形剤である。  Further, the present invention (2) is the solidifying agent according to the above-mentioned invention (1), which is in the form of granules and Z or fine granules.
更に、 本発明 (3) は、 該塩がブドウ糖と塩化カルシウムと酢酸ナトリウムと の反応生成物である、 前記発明 (1) 又は (2) の透析用固形剤である。  Further, the present invention (3) is the solid preparation for dialysis according to the above-mentioned invention (1) or (2), wherein the salt is a reaction product of glucose, calcium chloride and sodium acetate.
また、 本発明 (4) は、 該被覆層が融着状である、 前記発明 (1) 〜 (3) のい ずれか一つの透析用固形剤である。 The present invention (4) is the solid agent for dialysis according to any one of the inventions (1) to (3), wherein the coating layer is in a fused state.
更に、 本発明 (5) は、 前記発明 (1) 〜 (4) のいずれか一つの透析用固形 剤と重炭酸ナトリゥムを含む固形剤とからなる重炭酸透析用固形剤である。  Further, the present invention (5) is a solid agent for bicarbonate dialysis comprising the solid agent for dialysis according to any one of the inventions (1) to (4) and a solid agent containing sodium bicarbonate.
また、 本発明 (6) は、 透湿度 (40°C、 90%RH) 2. 0 g/m2 - 24 h r 以下であり、 背面電極効果を有する積層構造の防湿包材に収納されている、 前記 発明 (1) 〜 (5) のいずれか一つの透析用固形剤である。 Further, the present invention (6) has a moisture permeability (40 ° C., 90% RH) of 2.0 g / m 2 -24 hr or less, and is housed in a moisture-proof packaging material having a laminated structure having a back electrode effect. The solid agent for dialysis according to any one of the inventions (1) to (5).
更に、 本発明 (7) は、 塩化ナトリウム、 塩化カリウム、 塩化カルシウム、 塩 化マグネシウム及び酢酸ナトリゥムからなる電解質組成物、' pH調整剤並びにブ ドウ糠を原料として製造される透析用固形剤の製造方法において、 該固形剤の 1種以上の原料成分を含む粉体及び Z又は粒体に、 該粉体及び/又は粒体の重量 に対して 0. 1〜 2重量。/。の水を、 精製水又は該固形剤の原料成分を 1種以上含 有する水溶液の形態で混合し (ここで、 該混合物は、 少なくともブドウ糖、 塩化 カルシウム及び酢酸ナトリゥムを含む)、 50 °C以下で 1分以上、 該混合物 1 k g あたり 0. 003 kW/k g以上の剪断力下で該混合物を攪拌造粒する工程を含 むことを特徴とする製造方法である。 Further, the present invention (7) provides an electrolyte composition comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and sodium acetate, a pH adjuster, and a solid preparation for dialysis produced from bead bran. In the method, for the powder and Z or granules containing one or more raw material components of the solid agent, 0.1 to 2 weight based on the weight of the powder and / or granules. /. Water in the form of purified water or an aqueous solution containing at least one raw material component of the solid agent (wherein the mixture contains at least glucose, calcium chloride and sodium acetate) at 50 ° C or lower. Agitating and granulating the mixture under a shearing force of 0.003 kW / kg or more per kg of the mixture for 1 minute or more. The manufacturing method is characterized in that:
尚、 本明細書における 「剪断力」 は、 以下式で算出された値をいう :  In this specification, “shearing force” refers to a value calculated by the following equation:
剪断力 [kW/kg] =={ (負荷時の電流値 [A]-無負荷時の電流値 [A])/定格電流値 [A]} Xモータ一容量 [kW] /内容物重量 [kg]  Shearing force [kW / kg] == {(current value at load [A] -current value at no load [A]) / rated current value [A]} X motor capacity [kW] / content weight [ kg]
負荷時の電流値:撹拌造粒時における撹拌型混合造粒装置の撹拌モーターの電流 値 [A] Current value under load: Current value of stirring motor of stirring type mixing granulator during stirring granulation [A]
無負荷時の電流値:空運転時 (撹拌造粒時と同回転数) における該装置の撹拌 モーターの電流値 [A] Current value under no load: current value of the stirring motor of the device during idle operation (same number of revolutions as during stirring granulation) [A]
定格電流値:該装置の撹拌モーターの定格電流値 [A] Rated current value: Rated current value of the stirring motor of the device [A]
モーター容量:該装置の撹拌モーターのモーター容量 [kW] Motor capacity: Motor capacity of the stirring motor of the device [kW]
内容物重量:撹拌造粒時における該装置内の該混合物重量 [kg] Content weight: Weight of the mixture in the device during stirring granulation [kg]
また、 本発明 (8) は、 該水溶液の粘度が 0. 00 l〜2Pa's である、 前記発 明 (7) の製造方法である。  Further, the present invention (8) is the production method according to the above-mentioned invention (7), wherein the aqueous solution has a viscosity of 0.001 to 2 Pa's.
更に、 本発明 (9) は、 該水溶液がブドウ糖と塩化マグネシウムを含む水溶液 である、 前記発明 (7) 又は (8) の製造方法である。  Furthermore, the present invention (9) is the production method according to the above invention (7) or (8), wherein the aqueous solution is an aqueous solution containing glucose and magnesium chloride.
また、 本発明 (1 0) は、 透析用固形剤が、 前記発明 (1) 〜 (6) のいずれ か一つの透析用固形剤である、 前記発明 (7) 〜 (9) のいずれか一つの製造方 法である。 図面の簡単な説明  Further, the present invention (10) provides the dialysis solid preparation according to any one of the inventions (7) to (9), wherein the dialysis solid preparation is any one of the inventions (1) to (6). There are two manufacturing methods. BRIEF DESCRIPTION OF THE FIGURES
図 1は、 一見して表面や内部に粒子が確認できないタイプの、 本発明に係る固 形剤の断面の状態を示したイメージ図である。 尚、 図中、 1は被覆層、 2は母粒 子を示す。  FIG. 1 is an image diagram showing a cross-sectional state of a solidifying agent according to the present invention of a type in which particles cannot be recognized on the surface or inside at a glance. In the figure, 1 indicates a coating layer and 2 indicates a mother particle.
図 2は、 表面及び内部に粒子が存在することが確認できるタイプの、 本発明に 係る固形剤の断面の状態を示したイメージ図である。 尚、 図中、 Aは粒子、 Bは 融着層を示す。  FIG. 2 is an image diagram showing a cross-sectional state of a solid agent according to the present invention of a type in which particles can be confirmed on the surface and inside. In the figures, A indicates particles, and B indicates a fusion layer.
図 3は、 無数の粒子が堆積したように見える、 従来の固形剤の断面の状態を示 したイメージ図である。 尚、 図中、 1' は堆積層、 2' は母粒子、 Cは粒子を示 す。 図 4は、 本発明における 「融着状」 の意義を示したイメージ図である。 FIG. 3 is an image diagram showing a state of a cross section of a conventional solid agent in which countless particles appear to be deposited. In the figure, 1 'indicates a sedimentary layer, 2' indicates a base particle, and C indicates a particle. FIG. 4 is an image diagram showing the significance of “fused” in the present invention.
図 5は、 従来技術における 「堆積状」 の意義を示したイメージ図である。 尚、 図中、 Dは結合剤を示す。  FIG. 5 is an image diagram showing the significance of “stacking” in the conventional technology. In the figures, D indicates a binder.
図 6は、 実施例 1で得られた透析用固形剤のデジタル顕微鏡写真である (デジ タル写真)。  FIG. 6 is a digital micrograph of the solid preparation for dialysis obtained in Example 1 (digital photograph).
図 7は、 実施例 1で得られた透析用固形剤の電子顕微鏡写真である (デジタル 写真)。  FIG. 7 is an electron micrograph of the solid preparation for dialysis obtained in Example 1 (digital photograph).
図 8は、 実施例 1で得られた透析用固形剤の母粒子の元素分析結果 (ェネル ギー分散型 X線分析装置 (E D X) ) を示す。  FIG. 8 shows an elemental analysis result (energy dispersive X-ray analyzer (EDX)) of the base particles of the solid preparation for dialysis obtained in Example 1.
図 9は、 実施例 1で得られた透析用固形剤の被覆層の元素分析結果 (ェネル ギー分散型 X線分析装置 (E D X) ) を示す。  FIG. 9 shows the results of elemental analysis (energy dispersive X-ray analyzer (EDX)) of the coating layer of the solid agent for dialysis obtained in Example 1.
図 1 0は、 実施例 1で得られた透析用固形剤の薄膜 X線回折の結果を示す。  FIG. 10 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Example 1.
図 1 1は、 実施例 2で得られた透析用固形剤の薄膜 X線回折の結果を示す。  FIG. 11 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Example 2.
図 1 2は、 比較例 1で得られた透析用固形剤の電子顕微鏡写真である (デジタ ル写真)。  FIG. 12 is an electron micrograph of the dialysis solid obtained in Comparative Example 1 (digital photograph).
図 1 3は、 比較例 1で得られた透析用固形剤の薄膜 X線回折の結果を示す。  FIG. 13 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Comparative Example 1.
図 1 4は、 比較例 2で得られた透析用固形剤の薄膜 X線回折の結果を示す。 発明を実施するための最良の形態  FIG. 14 shows the result of thin-film X-ray diffraction of the solid preparation for dialysis obtained in Comparative Example 2. BEST MODE FOR CARRYING OUT THE INVENTION
まず、 本発明に係る透析用固形剤について説明する。 本発明に係る透析用固形 剤は、 組成的には、 従来のそれと本質的には変わりなく、 各種電解質 (塩化ナト リウム、 塩化カリウム、 塩化カルシウム、 塩化マグネシウム及び酢酸ナトリウ ム)、 p H調整剤及びブドウ糠からなるものである。 ここで、 p H調整剤としては、 薬理学的に許容されるものであれば特に制限されるものではなく、 例えば、 酢酸、 塩酸等の液体状の酸、 乳酸、 クェン酸、 りんご酸、 二酢酸ナトリウム等の固体状 の酸を挙げることができ、 これらを単独で乃至は複数組み合わせて用いてもよレ、。 好適には、 酢酸及び二酢酸ナトリウムである。  First, the solid agent for dialysis according to the present invention will be described. The solid composition for dialysis according to the present invention is essentially the same in composition as conventional ones, and includes various electrolytes (sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate), pH adjusters. And grape bran. Here, the pH adjuster is not particularly limited as long as it is pharmacologically acceptable. Examples thereof include liquid acids such as acetic acid and hydrochloric acid, lactic acid, citric acid, malic acid, and diacid. Examples thereof include solid acids such as sodium acetate, and these may be used alone or in combination of two or more. Preferably, acetic acid and sodium diacetate.
本発明に係る透析用固形剤の特徴は、 特定の塩を含む被覆層で母粒子が覆われ ている点にある。 まず、 はじめに本発明に係る被覆層につき説明する。 該被覆層は、 薄膜 X線回 折において、 2 0 = 2 1 . 3〜2 1 . 5 ° 及び 2 0 = 2 7 . 6〜2 7 . 8 ° ( C u K a ; λ = 1 . 5 4 0 5 8 Α、 入射角 0 = Γ :)に特定のピークを有する塩を含む。 ここで、 該塩の必須成分の特定を消去法により行った結果、 該塩がブドウ糖と塩 化カルシウムと酢酸ナトリウムとの反応生成物であることが判明した。 A feature of the solid agent for dialysis according to the present invention is that the base particles are covered with a coating layer containing a specific salt. First, the coating layer according to the present invention will be described. In the thin film X-ray diffraction, the coating layer has a thickness of 20 = 21.3 to 21.5 ° and 20 = 27.6 to 27.8 ° (CuK a; λ = 1.5). 4 0 5 8 Α, Includes a salt having a specific peak at an incident angle 0 = Γ :). Here, as a result of specifying the essential components of the salt by the elimination method, it was found that the salt was a reaction product of glucose, calcium chloride, and sodium acetate.
通常、 原料である塩化カルシウムは、 ブドウ糖と共存するとブドウ糖の分解を 促進させ、 著しく剤の保存安定性を劣化させるが、 本発明に係る透析用固形剤は、 攪拌造粒工程において大半の塩化カルシウムがブドウ糖及び酢酸ナトリウムと特 異的に反応して該塩として被覆層に含まれると推定されることから、 保存安定性 が極めて良好である。 また、 該塩を含む透析用固形剤は、 所定の水に溶解すれば 所定の電解質イオン濃度及びブドウ糖濃度になる.ことが確認されている。  Normally, calcium chloride as a raw material, when coexisting with glucose, promotes the decomposition of glucose and significantly degrades the storage stability of the agent. However, the solid agent for dialysis according to the present invention uses most of calcium chloride in the stirring granulation process. Is presumed to be specifically reacted with glucose and sodium acetate and contained in the coating layer as the salt, so that the storage stability is extremely good. In addition, it has been confirmed that the solid agent for dialysis containing the salt has a predetermined electrolyte ion concentration and a predetermined glucose concentration when dissolved in predetermined water.
尚、 本発明に係る被覆層は、 該塩以外の成分を含んでいてもよく、 例えば、 固 形剤の原料である、 塩化ナトリウム、 塩化カリウム、 塩化マグネシウム、 酢酸ナ トリゥム、 ブドウ糖及び/又は ρ Η調整剤を含んでいてもよい。  The coating layer according to the present invention may contain components other than the salt. For example, sodium chloride, potassium chloride, magnesium chloride, sodium acetate, glucose and / or ρ ΗIt may contain a regulator.
また更に、 本発明に係る被覆層は融着状である。 まず、 「融着状」 とは、 溶融物 を固化させたときのような^であることを意味し、 「凝集状」 ともいい得る。 尚、 外観が融着状であるという意であり、 実際に融点以上に加熱して溶融させること を意味するものではない。 また、 非晶質状 (これは、 非晶質より構成されるとい う意ではなく、 外観が非晶質であるように見えるさまを意味する) という表現も 可能である。 尚、 すべてが一体的に融着していなくともよく、 表面や内部に粒子 を含んでいる状態であってもよい。 ここで、 従来の透析用固形剤の被覆層と本発 明に係る 「融着状被覆層」 との違いをイメージ図をもって説明する。 まず、 従来 の被覆層は、 図 3に示すように、 無数の粒子 Cが母粒子 2 ' 上に堆積したような 構造となっている。 そして、 図 5に示すように、 粒子 Cと粒子 Cは、 結合剤 Dを 介して結合している力、、 単に粒子上に乗った構造を採っていると理解される。 他 方、 本発明に係る 「融着状被覆層」 は、 図 1に示すように、 粒子が堆積したとい うよりも、 大部分の粒子が融着して一体化してしまったかのような外観を有する。 但し、 大部分が一体化しているような外観であればよく、 図 2や図 4に示すよう に被覆層 1の表面や内部に、 融着状態にない粒子 Αが存在していても、 本発明に いう 「融着状被覆層」 に該当する。 Still further, the coating layer according to the present invention is in a fused state. First, "fused" means ^ as when a melt is solidified, and may be referred to as "agglomerated". It should be noted that the appearance is a fused state, and does not mean that the material is actually heated to a melting point or more to be melted. It can also be described as being amorphous (this does not mean that it is composed of amorphous but means that the appearance appears to be amorphous). Not all of them need to be fused together, and they may be in a state of containing particles on the surface or inside. Here, the difference between the conventional coating layer of the solid agent for dialysis and the “fused coating layer” according to the present invention will be described with reference to an image diagram. First, as shown in FIG. 3, the conventional coating layer has a structure in which innumerable particles C are deposited on the base particles 2 ′. And, as shown in Fig. 5, it can be understood that the particles C and the particles C have a force of binding via the binder D, that is, a structure simply riding on the particles. On the other hand, the “fused coating layer” according to the present invention, as shown in FIG. Have. However, it is sufficient if the external appearance is such that most of the particles are integrated, and even if particles に that are not in a fused state exist on the surface or inside of the coating layer 1 as shown in FIGS. Invention "Fused coating layer".
次に、 本発明に係る母粒子につき説明する。 本発明に係る母粒子は、 特に限定 されず、 固形剤の原料成分からなる。 例えば、 塩ィ匕ナトリウムからなる母粒子、 他の成分 (例えば、 塩化カリウム、 酢酸ナトリウム、 ブドウ糖) からなる母粒子 を挙げることができる。 尚、 例えば、 実施例においては、 大半の粒子の母粒子は 塩ィ匕ナトリウムからなり、 残りの粒子の母粒子は他の原料成分からなる。 .  Next, the base particles according to the present invention will be described. The base particles according to the present invention are not particularly limited, and are composed of a raw material component of a solid agent. For example, base particles composed of sodium salt and mother particles composed of other components (for example, potassium chloride, sodium acetate, and glucose) can be exemplified. In the examples, for example, the base particles of most of the particles are made of sodium chloride, and the base particles of the remaining particles are made of other raw material components. .
以上述べたように、 被覆層中に該塩が含まれている限り、 例えば、 塩化ナトリ ゥムが被覆層に含まれていても、 ブドウ糖が母粒子に含まれていても、 更には、 固形剤の原料成分や反応生成物が、 母粒子 ·被覆層のいずれに含まれていても、 或いは両方に含まれていても構わない。 ただし、 塩化マグネシウムは被覆層に含 まれるのが好ましい。  As described above, as long as the salt is contained in the coating layer, for example, even if sodium chloride is contained in the coating layer, glucose is contained in the mother particles, and solid The raw material components and reaction products of the agent may be contained in either the base particles or the coating layer, or may be contained in both. However, magnesium chloride is preferably contained in the coating layer.
本発明に係る透析用固形剤は、 典型的には、 顆粒状及び/又は細粒状の造粒物 である。 そして、 その平均粒径は、 約 2 2 0〜 8 0 0 mであり、 被覆層の厚さ は 1 0〜7 0 μ πιで ることが好適である。 ここで、 該造粒物は、 母粒子の表面 に被覆層が形成された単独の粒子であってもよいし、 複数の被覆された母粒子が 被覆層を介して結合したものであってもよい。 造粒物のうち単独の粒子の形状は、 やや丸みを帯びた立方体のものが中心である。 他方、 被覆層を介して結合したも のは、 数個の被覆された立方体状の粒子が結合した形状である。  The solid agent for dialysis according to the present invention is typically a granular and / or fine granulated product. The average particle size is preferably about 220 to 800 m, and the thickness of the coating layer is preferably 10 to 70 μπι. Here, the granulated product may be a single particle in which a coating layer is formed on the surface of a base particle, or a product in which a plurality of coated base particles are bonded via a coating layer. Good. The shape of a single particle of the granulated material is mainly a slightly rounded cube. On the other hand, what is bound via the coating layer is a shape in which several coated cubic particles are bound.
次に、 本発明に係る透析用固形剤の製造方法につき説明する。 本発明に係る透 析用固形剤の製造方法は、 該固形剤の 1種以上の原料成分を含む粉体及び 又は 粒体に、 該粉体及び Z又は粒体の重量に対して 0 . 1〜2重量%の水を、 精製水 又は該固形剤の原料成分を 1種以上含有する水溶液の形態で混合し (ここで、 該 混合物は、 少なくともプドウ糖、 塩化カルシウム及び酢酸ナトリウムを含む)、 5 0 °C以下で 1分以上、 該混合物 1 k gあたり 0 . 0 0 3 k W/ k g以上の剪断 力下で該混合物を攪拌造粒する工程を含む。 以下に詳述する。  Next, a method for producing the solid agent for dialysis according to the present invention will be described. The method for producing a solid preparation for diffusion according to the present invention comprises the steps of: providing a powder and / or granules containing at least one raw material component of the solid preparation; 22% by weight of water in the form of purified water or an aqueous solution containing at least one raw material component of the solid agent (wherein the mixture contains at least pudose sugar, calcium chloride and sodium acetate), A step of stirring and granulating the mixture at a shearing force of not less than 0.003 kW / kg per 1 kg of the mixture at 50 ° C or less for 1 minute or more. Details will be described below.
まず、 本発明に係る 「粉体及び Z又は粒体」 について説明する。 本発明に係る 「粉体及び/又は粒体」 は、 該固形剤の 1種以上の原料成分 (塩化ナトリウム、 塩化カリウム、 酢酸ナトリウム、 塩化カルシウム、 塩化マグネシウム、 ブドウ糖 及ぴ p H調整剤からなる原料群から選択される 1種以上) からなる。 加えて、 該 粉体及び/又は粒体は、 基本的には乾燥形態にあり、 場合により、 液状の p H調 整剤が含浸した状態にある。 First, the “powder and Z or granule” according to the present invention will be described. The “powder and / or granule” according to the present invention comprises at least one raw material component (sodium chloride, potassium chloride, sodium acetate, calcium chloride, magnesium chloride, glucose, and a pH adjuster) of the solid agent. One or more selected from raw material groups). In addition, The powders and / or granules are basically in dry form, optionally impregnated with a liquid pH adjuster.
ここで、 「粉体及び 又は粒体 J として、 塩化ナトリウム、 塩化カリウム、 酢酸 ナトリウム、 ブドウ糖を用いる場合、 各粒子の粒子径は特に限定されるものでは ないが、 各粒子径の差ができるだけ小さくなるような組み合わせが、 均一性の保 持という面からは好ましい。 即ち、 平均粒径は 2 0 0〜6 0 0 μ πι程度のものが 好ましく、 それぞれの粒子の平均粒径の差が、 全粒子の平均粒径の 3 0 %以内に なるような組み合わせが好ましい。 また、 塩化カルシウムの粒径は、 ブドウ糖と 酢酸ナトリ.ゥムとの反応を促進させるため、 3 0 0 m以下が望ましい。  Here, `` When sodium chloride, potassium chloride, sodium acetate, or glucose is used as the powder and / or granules J, the particle size of each particle is not particularly limited, but the difference between the particle sizes is as small as possible. From the viewpoint of maintaining uniformity, the average particle diameter is preferably about 200 to 600 μπι, and the difference between the average particle diameters of the respective particles is The combination is preferably such that the average particle size of the particles is within 30%, and the particle size of calcium chloride is preferably not more than 300 m in order to promote the reaction between glucose and sodium acetate.
次に、 本発明に係る 「精製水又は該固形剤の原料成分を 1種以上含有する水溶 液」 の内、 「水溶液」 に関して説明する。 以下、 特記しない限り、 この水溶液を 「該水溶液」 という。 該水溶液の溶質は、 特に限定されず、 固形剤の原料成分で ある、 塩ィヒナトリウム、 塩化カリウム、 塩化カルシウム、 塩化マグネシウム、 酢 酸ナトリウム、 p H調整剤及びブドウ糖からなる群より選択される 1種以上であ る。 尚、 各成分は、 全量が溶解している必要は無く、 一部が固体状態であっても よい。  Next, the “aqueous solution” of the “aqueous solution containing one or more raw material components of purified water or the solid agent” according to the present invention will be described. Hereinafter, this aqueous solution is referred to as “the aqueous solution” unless otherwise specified. The solute of the aqueous solution is not particularly limited, and is one selected from the group consisting of sodium chloride salt, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, a pH adjuster, and glucose, which are raw material components of the solid agent. That is all. It is not necessary that all of the components are dissolved, and some of them may be in a solid state.
好ましい態様は、 ブドゥ糖及ぴ塩化マグネシゥムを含む水溶液である。 この場 合には、 より強固な被覆層を形成することができる。 ここで、 この水溶液におけ るブドウ糖濃度は、 好適には 1 0〜7 0重量%、 より好適には 2 0〜6 0重量% であり、 塩化マグネシウム(六水和物)の濃度は、 好適には 1 0〜7 0重量0/。、 よ り好適には 2 5〜6 0重量%である。 このように、 両者が共存した状態 {水溶液 の p Hが酸性状態になる (例えば約 4. 5 ) } では、 プドウ糖が安定保持され'ると 共に、 単独の溶解度より遥かに高濃度に両者を溶解させることができ、 しかもこ の水溶液の粘度を適度に低下させ、 造粒に好適な粘度に調整することができる。 このため、 他の造粒法に比べて極めて少量の水溶液で、 しかも短時間で全体を均 一に被覆することができる。 尚、 この水溶液は、 これら以外の成分を含んでいて もよく、 例えば、 塩化カルシウム等の電解質を更に含んでいる態様を挙げること ができる。 尚、 この水溶液は、 塩化マグネシウムの水溶液にブドウ糠を溶解する だけで簡単に調製できる。 該水溶液は、 粘度が 0 . 0 0 1〜 2 Pa' s であることが好適であり、 より好適に は 0 . 0 1〜1 . 5 Pa' s、 更に好適には 0 . 0 1 5〜 1 Pa' s である。 尚、 ここで の粘度は、 B型粘度計により測定された値を指す。 A preferred embodiment is an aqueous solution containing butdu sugar and magnesium chloride. In this case, a stronger coating layer can be formed. Here, the glucose concentration in this aqueous solution is preferably 10 to 70% by weight, more preferably 20 to 60% by weight, and the concentration of magnesium chloride (hexahydrate) is preferably There are 10-70 weight 0 /. More preferably, it is 25 to 60% by weight. Thus, in a state where both coexist {the pH of the aqueous solution becomes acidic (for example, about 4.5)}, the pudose is stably maintained and both the concentration is much higher than the solubility of a single substance. Can be dissolved, and the viscosity of the aqueous solution can be appropriately reduced, and adjusted to a viscosity suitable for granulation. For this reason, an extremely small amount of aqueous solution can be uniformly applied in a short time as compared with other granulation methods. In addition, this aqueous solution may contain components other than these, for example, an embodiment further including an electrolyte such as calcium chloride. This aqueous solution can be prepared simply by dissolving grape bran in an aqueous solution of magnesium chloride. The aqueous solution preferably has a viscosity of 0.01 to 2 Pa's, more preferably 0.01 to 1.5 Pa's, and still more preferably 0.01 to 15 Pa's. 1 Pa 's. The viscosity here indicates a value measured by a B-type viscometer.
「粉体及びノ又は粒体」 及び 「精製水又は該固彤剤の原料成分を 1種以上含有 する水溶液」 とからなる混合物は、 少なくともブドウ糖、 塩化カルシウム及び酢 酸ナトリウムを含有する。 ここで、 これら成分は、 粉体及び Z又は粒体にのみ含 まれていても、 水溶液にのみ含まれていても、 両者に含まれていてもよい。  A mixture consisting of “powder and powder or granules” and “purified water or an aqueous solution containing at least one raw material component of the solidifying agent” contains at least glucose, calcium chloride and sodium acetate. Here, these components may be contained only in the powder and Z or granules, may be contained only in the aqueous solution, or may be contained in both.
「粉体及び 又は粒体」 と 「水溶液』 の組み合わせの好適例を挙げると、 「粉体 及び 又は粒体」 1 塩化ナトリウム、 塩化カリウム、 酢酸ナトリウム、 プドウ 糖を含み、 任意成分として、 塩化カルシウムを含むものであり、 「水溶液」 力 ブ ドウ糖、 塩化マグネシウムを含み、 任意成分として塩化カルシウムを含むもので 尚、 固形剤の全原料を 「粉体及び/又は粒体」 + 「水溶液」 に使用する必要は なく、 原料の一部を以後の工程で添加してもよい。 例えば、 p H調整剤に関して は、 「粉体及び Z又は粒体」 中にあらかじめ添加しても、 造粒中に添加しても、 乾 燥前に添加しても、 乾燥中に添加しても、 乾燥後に添加してもよい。  Preferable examples of the combination of "powder and / or granule" and "aqueous solution" include "powder and / or granule" .1 Includes sodium chloride, potassium chloride, sodium acetate, pudose sugar, and optionally calcium chloride. "Aqueous solution" contains glucose and magnesium chloride, and optionally contains calcium chloride.All raw materials of the solid preparation are defined as "powder and / or granules" + "aqueous solution". It is not necessary to use it, and part of the raw material may be added in the subsequent steps. For example, with respect to pH adjusters, they can be added in advance in “powder and Z or granules”, added during granulation, added before drying, or added during drying. May also be added after drying.
次に、 製造方法における各種条件につき説明する。 まず、 系に添加する 「精製 水又は該固形剤の原料成分を 1種以上含有する水溶液」 における水の量は、 系内 に存在する 「粉体及び 又は粒体」 の総量の 0 . 1〜2 . 0重量%が好ましく、 より好適には 0 . 2〜1 . 4重量%である。 ここで、 系に添加する水の量には、 原料中の結晶水は含まれない。  Next, various conditions in the manufacturing method will be described. First, the amount of water in the “purified water or the aqueous solution containing at least one raw material component of the solid agent” to be added to the system is from 0.1 to the total amount of the “powder and / or granules” present in the system. It is preferably 2.0% by weight, more preferably 0.2 to 1.4% by weight. Here, the amount of water added to the system does not include water of crystallization in the raw materials.
' 精製水又は該水溶液添加から造粒完了までの時間は、 該塩の反応に要する時間、 生成した造粒物の含量均一性及びさらさら化 (水分を約 2重量%含有するにもか かわらず、 流動性が良く、 防湿性が高く、 付着や凝集の要因となる自由水が、 被 覆層の表面にほとんどない造粒物になること) を考慮すると、 1分以上が好適で あり、 より好適には 3分以上であり、 更に好適には 1 0分以上である。 また、 破 碎防止の観点から 3 0分以下が好適である。  '' The time from the addition of purified water or the aqueous solution to the completion of granulation is as follows: the time required for the reaction of the salt, the uniformity of the content of the formed granules, and the smoothness (even though the water content is about 2% by weight) Considering that the fluidity is good, the moisture resistance is high, and free water that causes adhesion and coagulation hardly forms on the surface of the coating layer), it is preferable that the time is 1 minute or more. It is preferably at least 3 minutes, more preferably at least 10 minutes. Also, from the viewpoint of preventing fracture, the time is preferably 30 minutes or less.
次に、 撹拌時に加える剪新力について説明する。 まず、 本発明に係る剪断力の 定義につき説明する。 .撹拌型混合造粒装置を使用した場合、 本発明に係る撹拌造 粒時において、 撹拌翼の回転によって撹拌翼と該装置内壁との間で該混合物に剪 断力が加わる。 この剪断力の大きさを、 該装置の撹拌モーターの負荷量 (モー ターの電流値) を用いて前記式にて算出し、 その値を該混合物 1 k gあたりに加 えた剪断力とした。 次に、 必要な該剪断力は、 0. 003 kWZk g以上であり、 好適には 0. 01 kW/k gであり、 更に好適には 0. 05 kW/k g以上であ る。 また、 上限に関しては、 内温上昇や破砕防止の観点から、 0. l kW/k g 以下であることが好適である。 Next, the shearing force applied during stirring will be described. First, the definition of the shearing force according to the present invention will be described. When a stirring-type mixing granulator is used, the stirring granulation according to the present invention At the time of granulation, a shear force is applied to the mixture between the stirring blade and the inner wall of the device due to the rotation of the stirring blade. The magnitude of this shearing force was calculated by the above equation using the load of the stirring motor of the apparatus (motor current value), and the value was defined as the shearing force applied per kg of the mixture. Next, the required shearing force is not less than 0.003 kWZkg, preferably not less than 0.01 kW / kg, and more preferably not less than 0.05 kW / kg. Also, the upper limit is preferably 0.1 kW / kg or less from the viewpoint of increasing the internal temperature and preventing crushing.
また、 攪拌造粒を実施する温度は、 常温付近の温度で充分であり、 プドウ糖の 分解防止に極めて有効な温度で造粒を実施できる。 すなわち、 本発明の造粒を実 施する温度は、 該塩生成の観点から、 内温 50°C以下であることが必須である。 下限値は、 特に限定されないが、 好適には o°c以上である。 尚、 より好適には In addition, the temperature at which stirring granulation is performed is sufficient at a temperature around room temperature, and granulation can be performed at a temperature that is extremely effective in preventing decomposition of pudose. That is, it is essential that the temperature at which the granulation of the present invention is carried out is not more than 50 ° C. from the viewpoint of salt formation. The lower limit is not particularly limited, but is preferably at least o ° c. In addition, more preferably
10〜50°Cであり、 最も好ましくは 20〜40°Cである。 It is 10 to 50 ° C, most preferably 20 to 40 ° C.
該粉体及び/又は粒体中に精製水ゃ該水溶液を添加する方法であるが、 特に制 限はなく、 一括添加もしくは分割添加でもよく、 噴霧する方式であってもよい。 また、 精製水又は該水溶液の温度 (添加前) は、 好適には、 15〜50°Cである。 尚、 攪拌造粒工程で使用する攪拌型混合造粒装置としては、 高速攪拌型造粒装 置が好適である。 操作条件は、 通常造粒する一般的条件の範囲内で目的は充分達 成される。  This is a method of adding purified water / the aqueous solution to the powder and / or the granules, but is not particularly limited, and may be a batch addition or a divided addition, or a spraying method. The temperature of the purified water or the aqueous solution (before addition) is preferably 15 to 50 ° C. In addition, as a stirring-type mixing granulation apparatus used in the stirring-granulation step, a high-speed stirring-type granulation apparatus is suitable. The operating conditions are sufficiently achieved within the range of general conditions for granulation.
造粒工程以降の工程や使用する装置、 操作条件は特に限定されないが、 得られ た造粒物を乾燥し、 必要に応じて、 乾燥前又は後に pH調整剤を添加混合し、 整 粒して顆粒状及び Z又は細粒状の本透析用固形剤を得る。  The steps after the granulation step, the equipment to be used, and the operating conditions are not particularly limited, but the obtained granules are dried, and if necessary, before or after drying, a pH adjuster is added and mixed, and the granules are granulated. A granulated and Z- or fine-grained solid for dialysis is obtained.
本発明に係る透析用固形剤と重炭酸ナトリゥムを所定の水に溶解すれば重炭酸 透析液を、 例えば下記の濃度に調整することができる:  By dissolving the solid agent for dialysis according to the present invention and sodium bicarbonate in predetermined water, the bicarbonate dialysate can be adjusted to, for example, the following concentrations:
Na+ 125〜150 mE q/1 Na + 125-150 mE q / 1
K+ 1. 0〜3. 0 mE q/1 K + 1.0 to 3.0 mE q / 1
C a2+ 1. 5-3. 5 mEq/1 C a 2+ 1.5-3.5 mEq / 1
Mg2+ 0. 5~1. 5 mEq/1 Mg 2+ 0.5 to 1.5 mEq / 1
C I— 90. 0〜135 mE q/ 1  C I— 90.0 to 135 mE q / 1
CH3C〇2一 5. 0〜: 10. 0 mEq/1 HCO3" 20. 0〜30. 0 mEq/1 CH 3 C〇 2 1 5.0 to: 10.0 mEq / 1 HCO 3 "20.0-30.0 mEq / 1
ブドウ糖 0. 5〜2. 5 g/1 Glucose 0.5-2.5 g / 1
この様にして得られる透析用固形剤の包装材料としては防湿性能が良く、 しか も背面電極効果を有するものが好ましい。 従来より帯電防止剤を樹脂に練りこん でフィルムを作成し、 帯電防止機能を有する包装材料に加工して使用された例は あつたが、 樹脂からのブリード現象により製品に異物が混入するなどの不都合が 見られた。 これに比べ、 本発明において帯電防止剤はフィルムの接着に使用する 接着剤中に含まれているためフィルムを浸透することはなく、 プリード現象は起 こりえない。 帯電防止剤は透析用固形剤と接するフィルム面の裏側にある接着剤 中にあり、 背面まで帯電防止機能を有するラミネートフィルムである。 すなわち、 透湿度 (40。C、 90%RH) 2. Og/m2 - 24h r以下のフィルム、 例えば シリカ蒸着フィルムを用い、 静電防止个生接着剤、 例えばボンディップ (コニシ社 製) を用いて接着したラミネートフィルムを用いて加工した背面電極効果を有す る包装材料に透析用固形剤を充填、 包装するのが好ましい。 その様な積層構造を 有するラミネートフィルムの構成例としては、 As the packaging material for the solid preparation for dialysis obtained in this manner, a material having good moisture-proof performance and having a back electrode effect is preferable. In the past, there was an example where a film was made by kneading an antistatic agent into a resin and then processed into a packaging material having an antistatic function.However, foreign materials mixed into the product due to the bleeding phenomenon from the resin were used. Inconvenience was seen. In contrast, in the present invention, since the antistatic agent is contained in the adhesive used for bonding the film, it does not penetrate the film, and the bleeding phenomenon does not occur. The antistatic agent is contained in the adhesive on the back side of the film surface in contact with the solid agent for dialysis, and is a laminated film having an antistatic function up to the back surface. That is, moisture permeability (40.C, 90% RH) 2. Og / m 2 - 24h r following film, for example, using a silica-deposited film, antistatic个生adhesive, for example Bonn dip (Konishi Co., Ltd.) It is preferable to fill and package a dialysis solid in a packaging material having a back electrode effect, which is processed using a laminated film adhered and used. Examples of the configuration of a laminated film having such a laminated structure include:
PETZS i Ox/ボンディップ/ PE、 PETZS i O x / Bondip / PE,
PVA/S i Ox/ボンディップ/ ΡΕ、 PVA / S i O x / bondip //,
ONY/S i〇x/ボンディップ ZPE、 ONY / S i〇 x / Bondip ZPE,
PET/S i Ox/ボンディップ /CPP、 PET / S i O x / bondip / CPP,
OPP/S i Ox/ボンディップ ZCPP、 OPP / S i O x / Bondip ZCPP,
を挙げることができ、 これを包装材料に加工して用いることができる。 ラミネー トフイルムは公知の方法により容易に製造できる。 製造方法の一例としては、 静 電防止性接着剤の必要量を計り取り、 必要により溶剤で希釈するなどして液が均 一になるように混合し、 グラビアコーター、 リバースコーター等のコーターを用 いて上記のフィルムに塗布し、 温風乾燥して完全に硬化させる方法を挙げること ができる。 得られたラミネートフィルムはヒートシールすることによつて包装材 料に加工することができる。 実施例 以下に本発明の実施例を示して、 更に具体的に説明する。 These can be processed into packaging materials and used. The laminating film can be easily produced by a known method. As an example of the production method, measure the required amount of the antistatic adhesive, dilute it with a solvent if necessary, mix the liquid evenly, and use a coater such as a gravure coater or reverse coater. Then, it is applied to the above-mentioned film, dried with hot air, and completely cured. The obtained laminated film can be processed into a packaging material by heat sealing. Example Hereinafter, the present invention will be described more specifically with reference to Examples.
[実施例 1]  [Example 1]
塩化ナトリウム 5000. Og、 塩化カリウム 121. 6 g、 塩化カルシウム 178. 5g、 酢酸ナトリウム 667. 4g、 ブドウ糖 760. 2g を高速攪拌型 造粒装置 (深江パゥテック株式会社製 ハイスピードミキサー F S— GS— Sodium chloride 5000. Og, potassium chloride 121.6 g, calcium chloride 178.5 g, sodium acetate 667.4 g, glucose 760.2 g, high-speed stirring granulator (High speed mixer FS—GS—manufactured by Fukae Patech Co., Ltd.)
25 J) に添加し混合攪拌した。 回転数 6 Orpm (剪断力 0. 04 kW/k g) で 混合攪拌しながら、 内温が 25DCで、 あらかじめ調製しておいたブドウ糖 54. 6 g と塩ィ匕マグネシウム 82. 8 g を精製水 36. 4 g に溶解した液温が25 J) and mixed and stirred. While mixing agitation at a rotation number 6 Orpm (shear 0. 04 kW / kg), at an internal temperature of 25 D C, previously prepared glucose had been 54. purification 6 g and Shioi匕magnesium 82. 8 g The temperature of the solution dissolved in 36.4 g of water is
30°Cの水溶液 (粘度: 0. 035Pa's) を添加した。 添加直後に湿潤な粒子状 であった内容物が、 15分間混合攪拌するとさらさらとした顆粒状となった。 一 且造粒物を取り出して水分が 0. 5重量%以下になるまで乾燥した。 得られた造 粒物に酢酸 98. 3 g を添加し 5分混合攪拌した後、 造粒物を取り出し整粒して 顆粒状及ぴ細粒状の製剤を得た。 An aqueous solution (viscosity: 0.035 Pa's) at 30 ° C was added. Immediately after the addition, the contents, which were in the form of wet particles, became smooth granules after mixing and stirring for 15 minutes. The granules were taken out and dried until the water content became 0.5% by weight or less. 98.3 g of acetic acid was added to the obtained granules, mixed and stirred for 5 minutes, and then the granules were taken out and sized to obtain a granular and fine granular preparation.
[実施例 2]  [Example 2]
塩化ナトリウム 5000. Og、 塩化カリウム 122. 7 g、 塩化カルシウム 181. 5g、 酢酸ナトリウム 202. 3 g、 ブドウ糖 767. 6 g を高速攪拌型 造粒装置に添加し混合撹拌した。 回転数 7 Orpm (剪断力 0. 06 kW/k g) で 混合撹拌しながら、 內温が 25°Cで、 あらかじめ調製しておいたブドウ糖 55. 2 g と塩化マグネシウム 83. 7g を精製水 55. 2 g に溶解した液温が 30°Cの水溶液 (粘度: 0. 043Pa's) を添加した。 添加直後に湿潤な粒子状 であった内容物が、 10分間混合撹拌するとさらさらとした顆粒状となった。 こ の造粒物を取り出し、 水分が 0. 5重量%以下になるまで乾燥した。 更に造粒物 にあらかじめ調製しておいた酢酸 98. 7gを酢酸ナトリウム 202. 0gに吸着 させたものを添加し、 撹拌混合した後、 整粒して顆粒状及び細粒状の製剤を得た。  5000. Og of sodium chloride, 122.7 g of potassium chloride, 181.5 g of calcium chloride, 202.3 g of sodium acetate, and 766.6 g of glucose were added to a high-speed agitation type granulator and mixed and stirred. While mixing and stirring at a rotation speed of 7 Orpm (shear force: 0.06 kW / kg), at a temperature of 25 ° C, 55.2 g of glucose and 83.7 g of magnesium chloride prepared in advance were purified water. An aqueous solution (viscosity: 0.043 Pa's) having a temperature of 30 ° C. dissolved in 2 g was added. Immediately after the addition, the contents in the form of wet particles became smooth granules after mixing and stirring for 10 minutes. The granules were taken out and dried until the water content became 0.5% by weight or less. Further, 98.7 g of acetic acid prepared in advance and adsorbed on 202.0 g of sodium acetate was added to the granulated product, and the mixture was stirred and mixed, and then sized to obtain a granular and fine granular preparation.
[比較例 1 ]  [Comparative Example 1]
塩化ナトリウム 1063. 5 g、 塩化カリウム 26. lg、 塩化マグネシウム 17. 8 g、 酢酸ナトリウム 86. lg、 ブドウ糖 175. 0 g、 精製水 20. 0g をエーダー (モリヤマ社製) に加え混合攪拌しながら加熱した。 55°C付近より 粘度が上がり始め、 内温 60°Cでペースト状になった。 塩化カルシウム 38. 6g を加えてそのまま 60°Cで攪拌を続けると、 内容物が嵩高くなり更に粘度が上昇 した。 酢酸 21. Og を添加して攪拌を,継続し、 内容物がさらさらしてくるが、 —部は塊状になり、 微粉状のものもあった。 内容物を取り出し、 整粒後乾燥して 製剤を得た。 Add 1063.5 g of sodium chloride, 26.lg of potassium chloride, 17.8 g of magnesium chloride, 86.lg of sodium acetate, 175.0 g of glucose, and 20.0 g of purified water to an Eder (manufactured by Moriyama), and mix and stir. Heated. The viscosity began to increase from around 55 ° C, and became a paste at an internal temperature of 60 ° C. 38.6 g calcium chloride When the mixture was added and stirring was continued at 60 ° C., the contents became bulky and the viscosity further increased. Acetic acid 21. Og was added and stirring was continued to circulate the contents, but the-part became clumpy and some were finely powdery. The contents were taken out, sized, and dried to obtain a preparation.
[比較例 2]  [Comparative Example 2]
塩化カリ ウム 2 6. 1 g、 塩化マグネシウム 1 7. 8 g、 塩化カルシウム 38. 6 g及び酢酸ナトリウム 86. 1 gを精製水 400. Ogに溶解して水溶液 を調製した。 転動流動層造粒装置に塩化ナトリウム 1063. 6g とプドウ糖 175. Og を投入し、 給気温度 80°C、 ローター回転数 15 Orpm, 給気風量 0. 7 m3/分の条件下で、 前記水溶液を噴霧すると同時に乾燥させ、 造粒物を得 た。 整粒後、 得られた造粒物に酢酸 21. Ogを添加混合して製剤を得た。 An aqueous solution was prepared by dissolving 26.1 g of potassium chloride, 17.8 g of magnesium chloride, 38.6 g of calcium chloride and 86.1 g of sodium acetate in 400 g of purified water. Sodium chloride 1063. 6 g and Pudou sugars 175. Og were charged into a tumbling fluidized bed granulator, the air supply temperature 80 ° C, the rotor rotational speed 15 Orpm, under the conditions of supply air volume 0. 7 m 3 / min The aqueous solution was sprayed and dried at the same time to obtain a granulated product. After sizing, 21. Og of acetic acid was added to the obtained granules and mixed to obtain a preparation.
[比較例 3]  [Comparative Example 3]
塩化ナトリウム 1063. 6 g、 塩化カリウム 26. lg、 塩化マグネシウム 17. 8 g、 塩化カルシウム 38. 6g及び酢酸ナトリウム 86. lg、 ブドウ糖 175. 0g を 75 m程度に粉枠し、 混合した後、 圧縮回転式造粒機にて造粒 した。 整粒後、 得られた造粒物に酢酸を添加混合して製剤を得た。  1066.6 g of sodium chloride, 26.lg of potassium chloride, 17.8 g of magnesium chloride, 38.6 g of calcium chloride, 86.lg of sodium acetate, and 175.0 g of glucose are powder-framed to about 75 m, mixed, and compressed. Granulation was performed using a rotary granulator. After sizing, acetic acid was added to the obtained granules and mixed to obtain a preparation.
[試験例 1 ]  [Test Example 1]
実施例 1で得られた製剤の顕微鏡写真 (キーエンス社製) を図 6に示す。 この 図より、 実施例 1で得た本製剤が、 単独の粒子として存在したり、 各母粒子の複 数個が被覆層を介して結合した集合体として存在していることが分かる。 また、 同製剤のデジタル操作型電子顕微鏡 (日立製作所製) による被覆層の構造を図 7に示す。 この図より、 同製剤の被覆層が融着したような外観を有していること が確認できる。 更に、 母粒子及び被覆層の元素分析結果 (EDX) を図 8及び図 9に夫々示す。 図 8より、 母粒子として塩化ナトリウムが存在することが確認さ れた。 尚、 他の母粒子につき元素分析を行ってみたところ、 塩化カリウム、 酢酸 ナトリゥム及びブドウ糠が母粒子として存在することも確認された。  FIG. 6 shows a micrograph (manufactured by Keyence Corporation) of the preparation obtained in Example 1. From this figure, it can be seen that the present preparation obtained in Example 1 is present as a single particle, or as an aggregate in which a plurality of base particles are bonded via a coating layer. Fig. 7 shows the structure of the coating layer of the same preparation using a digitally operated electron microscope (manufactured by Hitachi, Ltd.). From this figure, it can be confirmed that the coating layer of the same preparation has an appearance as if fused. 8 and 9 show the results of elemental analysis (EDX) of the mother particles and the coating layer, respectively. From FIG. 8, it was confirmed that sodium chloride was present as mother particles. In addition, elemental analysis of the other mother particles confirmed that potassium chloride, sodium acetate and grape bran were present as mother particles.
また、 図 9より被覆層中には塩化マグネシウム、 塩化カリウム、 ブドウ糖など が存在することが確認された。  From Fig. 9, it was confirmed that magnesium chloride, potassium chloride, glucose and the like were present in the coating layer.
[試験例 2] 実施例 1、 実施例 2で得られた各製剤の薄膜 X線回折の結果を図 1 0、 図 1 1に示す。 [Test Example 2] The results of thin-film X-ray diffraction of each preparation obtained in Examples 1 and 2 are shown in FIGS. 10 and 11.
測定は、 製剤の被覆層構造をより明確にするために薄膜 X線回折法を用い、 薄 膜 X線回折装置 (CUKQ: : ;L= 1. 540 58 A、 入射角 0 = 1° ) にて行つ た。  The measurement was performed using a thin-film X-ray diffractometer (CUKQ ::; L = 1.54058 A, incident angle 0 = 1 °) using a thin-film X-ray diffraction method to clarify the coating layer structure of the drug product. I went.
試料作製方法について説明する。 試料は各製剤から約 0. 5 gを取り、 打錠機 を用いて厚みが一様な円盤状に圧縮成型した。 打錠圧力は製剤の母粒子が破碎し ない程度と.し、 試料の大きさは直径約 2 Omm、 厚さは約 2mmとした。  A sample preparation method will be described. Approximately 0.5 g of each sample was taken from each preparation and compression molded into a disk of uniform thickness using a tableting machine. The tableting pressure was such that the base particles of the drug product did not break, and the sample size was about 2 Omm in diameter and about 2 mm in thickness.
図 10、'図 11より、 ブドウ糖と塩化カルシウムと酢酸ナトリゥムの反応生成 物を示す 20 =21. 4° 及び 27. 7° 付近にピークが検出されているのがわ かる。  From FIGS. 10 and 11, it can be seen that peaks are detected at around 20 = 21.4 ° and 27.7 °, which indicate the reaction products of glucose, calcium chloride and sodium acetate.
[試験例 3]  [Test Example 3]
比較例 1で得られた製剤のうち、 1粒子を取り出してその断面をデジタル操作 型電子顕微鏡で観察したものが図 1 2である。 この図より、 実施例 1のそれとは 異なり、 該製剤においては、 微細な粒子が堆積した状態にあることが分かる。 また、 比較例 1及び比較例 2で得られた各製剤を、 試験例 2と同様の方法で測 定した薄膜 X線回折結果を図 1 3〜図 1 4に示す。 ブドウ糖と塩化カルシウムと 酢酸ナトリウムの反応生成物を示す 2 0 = 2 1. 4° 及ぴ 27. 7° 付近にピ一 クが検出されていないのがわかる。  Among the preparations obtained in Comparative Example 1, one particle was taken out, and its cross section was observed with a digitally operated electron microscope. From this figure, it can be seen that, unlike that of Example 1, in the preparation, fine particles were deposited. FIGS. 13 to 14 show thin-film X-ray diffraction results of the preparations obtained in Comparative Examples 1 and 2 measured in the same manner as in Test Example 2. It can be seen that no peak was detected at around 20 = 21.4 ° and 27.7 °, indicating the reaction product of glucose, calcium chloride, and sodium acetate.
[試験例 4]  [Test Example 4]
実施例 1で得られた製剤からランダムに 6箇所サンプリングを行い、 それぞれ の検体についてサンプル 8. 5 Og を水に溶かして正確に 20 Oml とし、 これを 50倍希釈して Na+、 K+、 Mg2+、 C a2+、 C 1—、 C H3C O〇—の各電解質濃度 を東ソ一社製イオンクロマトグラフにより測定した。 また、 ブドウ糖については、 同様にサンプル 8. 50g を水に溶かして正確に 100ml とし、 東ソ一社製液体 クロマトグラフにより測定した。 測定結果を表 1に示す。 表 1 Six samples were randomly sampled from the preparation obtained in Example 1, and 8.5 Og of sample was dissolved in water to make exactly 20 Oml for each sample, and this was diluted 50-fold to obtain Na + , K + , The concentration of each of the electrolytes Mg 2+ , Ca 2+ , C 1— and CH 3 CO— was measured by an ion chromatograph manufactured by Tosoh Corporation. For glucose, 8.50 g of the sample was dissolved in water to make exactly 100 ml, and the glucose was measured by liquid chromatography manufactured by Tosoh Corporation. Table 1 shows the measurement results. table 1
Figure imgf000017_0001
Figure imgf000017_0001
単位 ; ブ ドウ糖は g/L、 その他の成分は mEq/L  Unit: g / L for glucose, mEq / L for other components
[試験例 5 ] [Test Example 5]
実施例 2で得られた製剤の各成分濃度についても、 実施例 1と同様に行い、 そ の結果を表 2に示す。 The concentration of each component of the preparation obtained in Example 2 was carried out in the same manner as in Example 1, and the results are shown in Table 2.
表 2 Table 2
Figure imgf000018_0001
Figure imgf000018_0001
(注) 単位 ; ブ ドウ糖は g/L、 その他の成分は mEq/L  (Note) Unit: g / L for glucose, mEq / L for other components
[試験例 δ ] [Test Example δ]
実施例 1、 実施例 2、 比較例 1、 比較例 2の製剤をそれぞれアルミニウム製包 材に充填し、 ヒートシールした後、 4 0 °C (R H= 7 5 %) の条件下で安定性試 験を実施した。 ブドウ糖の分解率を測定するため第 1 4改正日本薬局方に記載の ブドウ糖注射液の純度試験の紫外可視吸光度測定法に基づき吸光度の測定を行つ た。 その結果を表 3に示す。 Each of the preparations of Example 1, Example 2, Comparative Example 1, and Comparative Example 2 was filled in an aluminum packaging material, heat-sealed, and then subjected to a stability test at 40 ° C (RH = 75%). The experiment was performed. In order to measure the glucose decomposition rate, the absorbance was measured based on the ultraviolet-visible absorbance measurement method of the purity test for glucose injection described in the Japanese Pharmacopoeia, 14th Edition. The results are shown in Table 3.
表 3 Table 3
Figure imgf000019_0001
Figure imgf000019_0001
[試験例 7] [Test Example 7]
実施例 1、 実施例 2及ぴ比較例 1の製剤 23 Og を 2検体ずつ量り取り、 それ ぞれ 1 3 OmmX 8 5腿のアルミニウム製包材に充填し、 ヒートシールした後、 40°C (RH= 75%) の条件下で 3 Okg の荷重を均等にかけ、 経時的に固結状 態を観察した。 固結試験の結果を表 ·4に示した。 サンプルは、 所定の時間荷重を かけた後開封し、 1 6メ ッシュのふるいで軽く篩過して篩い残の量を測定した。 篩い残が 10重量%以内の場合は〇、 10〜50重量%の場合は△、 それ以上は Xで表した。 表 4  23 Og of each of the preparations of Example 1, Example 2 and Comparative Example 1 was weighed in two samples at a time, and each was filled in an aluminum packaging material of 13 OmmX 85 thighs, heat-sealed, and then sealed at 40 ° C ( Under the condition of (RH = 75%), a load of 3 Okg was applied evenly, and the consolidated state was observed over time. Table 4 shows the results of the consolidation test. The sample was opened after applying a load for a predetermined period of time, lightly sieved with a 16-mesh sieve, and the amount of the unsieved residue was measured. The sieving residue is represented by 〇 when the content is within 10% by weight, the △ when the content is 10 to 50% by weight, and X when the remaining amount is more than 10%. Table 4
Figure imgf000019_0002
Figure imgf000019_0002
[試験例 8] [Test Example 8]
1000ml のビーカーに水 400ml(20°C)を入れ、 撹拌しながら実施例 2及 ぴ比較例 1〜3の各製剤を 12 Og投入し、 完全に溶解するまでの時間を測定し た。 測定結果を表 5に示す。 表 5
Figure imgf000020_0001
400 ml of water (20 ° C.) was placed in a 1000 ml beaker, and 12 Og of each of the preparations of Example 2 and Comparative Examples 1 to 3 was charged with stirring, and the time required for complete dissolution was measured. Table 5 shows the measurement results. Table 5
Figure imgf000020_0001
[試験例 9 ] [Test Example 9]
実施例 1、 実施例 2、 比較例 1及び比較例 2で得られた各製剤から 2 O g を採 取し、 クロ口ホルム 2 O ml を添加して軽く振り混ぜた後、 上澄みを採取した。 ま た、 同様に各製剤から 2 O g を採取して 5分間振とうし、 クロ口ホルム 2 O ml を 添加して軽く振り混ぜた後、 上澄みを採取した。 それぞれの試料の濁度試験を J I S K 0 1 0 1 「工業用水試験方法」 のカオリン標準液を用いる場合に準じ て行った。 振とうにより生じた微粉末の量の差を、 振とう前後の濁度の差として 評価した。 その結果は表 6に示す通りで、 本発明によって得られる製剤は比較例 と比較して微粉末の量が少なく、 振とうのような物理的な力によってもその影響 を受けにくいという結果が得られた。 表 6  2 Og was collected from each of the preparations obtained in Example 1, Example 2, Comparative Example 1 and Comparative Example 2, and 2 O ml of clonal form was added, and the mixture was gently shaken and the supernatant was collected. . Similarly, 2 Og was collected from each preparation, shaken for 5 minutes, added with 2 Oml of black-mouthed form, mixed gently, and the supernatant was collected. The turbidity test of each sample was performed in accordance with the case of using the kaolin standard solution of JIS K 0101 “Industrial water test method”. The difference in the amount of fine powder generated by shaking was evaluated as the difference in turbidity before and after shaking. The results are shown in Table 6, and the results show that the preparation obtained by the present invention had a smaller amount of fine powder than the comparative example, and was less susceptible to physical forces such as shaking. Was done. Table 6
Figure imgf000020_0002
このような融着した状態にある被覆剤で覆われた製剤中の各成分組成は表 1、 2に示す通り理論値に極めて近い組成の製剤になっており、 本発明の透析用固形 剤がそれぞれの成分において含量均一性が充分であることがわかる。 また、 安定 性試験の結果も表 3に示す通り優れたものであり、 表 4に示す通り固結試験の結 果も良好であり長期の保存が可能な製剤である。 また、 表 5に示すように、 溶解 速度が速く、 更には表 6に示すように粉立ちも極めて少ないために取り扱いやす い製剤となっている。 発明の効果
Figure imgf000020_0002
The composition of each component in the preparation covered with the coating agent in such a fused state is a preparation having a composition very close to the theoretical value as shown in Tables 1 and 2, and the solid preparation for dialysis of the present invention is It can be seen that the content uniformity of each component is sufficient. In addition, the results of the stability test are excellent as shown in Table 3, and as shown in Table 4, the results of the caking test are good and the product can be stored for a long period of time. In addition, as shown in Table 5, the dissolution rate is high, and as shown in Table 6, the formulation is easy to handle due to extremely low dusting. The invention's effect
本発明に係る固形剤は、 強固に融着した状態の被覆層が母粒子を被覆した造粒 物であり、 他の例えば、 塩化ナトリゥム、塩化力リゥム等の電解質、 ブドウ糖の水 溶液を嘖霧して被膜形成を行う噴霧造粒方法などで製造された被膜或いは図 3に 示したような被膜に比べ、 表面が緻密であるため、 外部要因の影響を受けにくく、 長期保存 '安定性に優れており、 更には、 流動性ゃ耐摩損性、 耐固結性も良好で 発塵しにくく溶解速度も速いため、 医療現場での溶解操作の作業性が従来と比較 して極めて良好であるという効果を奏する。  The solid agent according to the present invention is a granulated product in which the coating layer in a state of being strongly fused is coated with the mother particles, and other examples include electrolytes such as sodium chloride and chlorine-containing rim, and aqueous solutions of glucose. Compared to a film manufactured by spray granulation method or the like as shown in Fig. 3 or a film as shown in Fig. 3, the surface is denser, so it is less susceptible to external factors and has excellent long-term storage stability. It is said that the workability of the dissolution operation at the medical site is much better than before because it has good fluidity, good abrasion resistance and good consolidation resistance, hardly generates dust, and has a high dissolution rate. It works.
更には、.本発明に係る固形剤の製造方法によれば、 従来と比べて長時間加熱す る必要が無いので、 造粒中にブドウ糖が分解、 着色している危険性を回避できる と共に、 粉碎、 篩などの煩雑な操作を必要とすることなく、 含量均一性に優れた 固形剤を得ることができる。 具体的には、 本発明の製法によると、 湿潤な粒子状 であった混合物が、 常温付近で短時間に、 さらさらとした見かけ上乾燥した顆粒 状及び Z又は細粒状の造粒物となり、 容易に造粒が完了する。 したがって、 次ェ 程である移送、 乾燥、 混合等のハンドリングが極めて容易となる。  Further, according to the method for producing a solid preparation according to the present invention, it is not necessary to heat for a long time as compared with the conventional method, so that danger of glucose being decomposed and colored during granulation can be avoided, and A solid preparation having excellent content uniformity can be obtained without requiring complicated operations such as grinding and sieving. Specifically, according to the production method of the present invention, the mixture that has been in the form of wet particles becomes a smooth, apparently dry granule, Z or fine granule in a short time at around room temperature, and is easily formed. The granulation is completed. Therefore, handling such as transfer, drying, and mixing, which is the next step, becomes extremely easy.

Claims

請 求 の 範 囲 The scope of the claims
1. 塩化ナトリウム、 塩化カリウム、 塩化カルシウム、 塩化マグネシウム及び酢 酸ナトリゥムからなる電解質組成物、 p H調整剤並びにブドウ糖からなる透析用 固形剤において、 薄膜 X線回折で 2 0 = 2 1. 3〜2 1. 5° 及び 2 0 = 27. 6〜27. 8° (CuKa ; え = 1. 54058 A、 入射角 0 = 1° )に特 定のピークを.有する塩を含む被覆層で母粒子が覆われていることを特徴とする透 析用固形剤。 1. In the electrolyte composition consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, the pH adjuster and the solid preparation for dialysis consisting of glucose, 20 = 21. 21.5 ° and 20 = 27.6 to 27.8 ° (CuKa; e = 1.54058 A, incident angle 0 = 1 °) A solidifying agent for permeation characterized in that it is covered.
2. 顆粒状及び/又は細粒状である、 請求の範囲第 1項記載の透析用固形剤。  2. The solid preparation for dialysis according to claim 1, which is in the form of granules and / or fine granules.
3, 該塩がブドウ糖と塩化カルシウムと酢酸ナトリウムとの反応生成物である、 請求の範囲第 1項又は第 2項記載の透析用固形剤。 3. The solid agent for dialysis according to claim 1, wherein the salt is a reaction product of glucose, calcium chloride, and sodium acetate.
4. 該被覆層が融着状である、 請求の範囲第 1項〜第 3項のいずれ力一項記載の 4. The method according to any one of claims 1 to 3, wherein the coating layer is in a fused state.
,透析用固形剤。 , Solid for dialysis.
5. 請求の範囲第 1項〜第 4項のいずれか一項記載の透析用固形剤と重炭酸ナト リウムを含む固形剤とからなる重炭酸透析用固形剤。  5. A solid agent for bicarbonate dialysis, comprising the solid agent for dialysis according to any one of claims 1 to 4 and a solid agent containing sodium bicarbonate.
6. 透湿度 (40 、 90%RH) 2. 0 g/m2 - 24h r以下であり、 背面電極 効果を有する積層構造の防湿包材に収納されている、 請求の範囲第 1項〜第 5項 のいずれか一項記載の透析用固形剤。 6. moisture permeability (40, 90% RH) 2. 0 g / m 2 - 24h r or less, are housed in the moisture-proof packaging material of a laminated structure having a back electrode effect, claim 1, wherein, second Item 6. The solid preparation for dialysis according to any one of Items 5.
7. 塩化ナトリウム、 塩化カリウム、 塩化カルシウム、 塩化マグネシウム及び酢 酸ナトリゥムからなる電解質組成物、 p H調整剤並びにブドウ糖を原料として製 造される透析用固形剤の製造方法において、 該固形剤の 1種以上の原料成分を含 む粉体及び 又は粒体に、 該粉体及びノ又は粒体の重量に対して 0. 1〜 2重 量%の水を、 精製水又は該固形剤の原料成分を 1種以上含有する水溶液の形態で 混合し (ここで、 該混合物は、 少なくともブドウ糖、 塩化カルシウム及び酢酸ナ トリウムを含む)、 50°C以下で 1分以上、 該混合物 1 k gあたり 0. 003 k W/k g以上の剪断力下で該混合物を攪拌造粒する工程を含むことを特徴とする 製造方法。  7. In a method for producing a solid composition for dialysis produced from sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, a pH adjuster and glucose as raw materials, Powders and / or granules containing one or more kinds of raw material components are mixed with 0.1 to 2% by weight of water based on the weight of the powders and / or granules, and purified water or raw material components of the solid agent. (Herein, the mixture contains at least glucose, calcium chloride and sodium acetate) at a temperature of 50 ° C or less for 1 minute or more, and 0.003 per kg of the mixture. a process for agitating and granulating the mixture under a shearing force of kW / kg or more.
8. 該水溶液の粘度が 0. 001〜2Pa's である、 請求の範囲第 7項記載の製造 方法。 8. The method according to claim 7, wherein the aqueous solution has a viscosity of 0.001 to 2 Pa's.
9. 該水溶液がブドウ糠と塩化マグネシウムを含む水溶液である、 請求の範囲第 7項又は第 8項の製造方法。 9. The production method according to claim 7, wherein the aqueous solution is an aqueous solution containing grape bran and magnesium chloride.
10. 透析用固形剤が、 請求の範囲第 1項〜第 6項のいずれか一項記載の透析用 固形剤である、 請求の範囲第 7項〜第 9項のレ、ずれか一項記載の製造方法。  10. The solid preparation for dialysis is the solid preparation for dialysis according to any one of claims 1 to 6, wherein the solid preparation for dialysis is any one of claims 7 to 9, Manufacturing method.
PCT/JP2004/000892 2003-01-31 2004-01-30 Solid agent for dialysis and process for producing the same WO2004066977A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2005504763A JP4603977B2 (en) 2003-01-31 2004-01-30 Dialysis solid preparation and method for producing the same
HK06109554A HK1089089A1 (en) 2003-01-31 2006-08-28 Solid agent for dialysis and process for producingthe same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003-023261 2003-01-31
JP2003023261 2003-01-31
PCT/JP2003/007356 WO2004067014A1 (en) 2003-01-31 2003-06-10 Solid preparation for dialysis and process for producing the same
JPPCT/JP03/07356 2003-06-10

Publications (1)

Publication Number Publication Date
WO2004066977A1 true WO2004066977A1 (en) 2004-08-12

Family

ID=32827142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/000892 WO2004066977A1 (en) 2003-01-31 2004-01-30 Solid agent for dialysis and process for producing the same

Country Status (1)

Country Link
WO (1) WO2004066977A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007131563A (en) * 2005-11-09 2007-05-31 Manac Inc Solid formulation for dialysis and method for producing the same
JP2016153391A (en) * 2015-02-16 2016-08-25 日本合成化学工業株式会社 Anhydrous sodium acetate crystal
US9931453B2 (en) 2012-10-10 2018-04-03 Tomita Pharmaceutical Co., Ltd. Dialysis agent a containing acetic acid and acetate salt, and a two-part dialysis agent using thereof
US10525078B2 (en) 2013-10-02 2020-01-07 Tomita Pharmaceutical Co., Ltd. Solid dialysis A agent containing alkali metal diacetate, and two-part type low-acetate dialysis agent using same
CN113975292A (en) * 2021-12-28 2022-01-28 广州康盛生物科技股份有限公司 Preparation method of hemodialysis dry powder component A not prone to caking

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02311418A (en) * 1989-05-26 1990-12-27 Terumo Corp Pharmaceutical for hemodialysis and its production
EP0602921A1 (en) * 1992-12-14 1994-06-22 Tomita Pharmaceutical Corporation Limited Bicarbonate dialysis dialysate component and method of manufacture
JPH06335527A (en) * 1993-04-02 1994-12-06 Morishita Roussel Kk Sodium bicarbonate dialysis pharmaceutical
JPH0892071A (en) * 1994-09-27 1996-04-09 Morishita Roussel Kk Bicarbonate dialyzing agent
JPH0892070A (en) * 1994-09-27 1996-04-09 Morishita Roussel Kk Blood dialyzing agent
JPH11343230A (en) * 1998-05-27 1999-12-14 Nissho Corp Agent for solid sodium bicarbonate dialysis
JP2001149468A (en) * 1999-11-25 2001-06-05 Nissho Corp Solid sodium bicarbonate dialyzing agent and its preparation process
JP2002102337A (en) * 2000-09-27 2002-04-09 Nipro Corp Solid dialyzing pharmaceutical preparation and method of preparing for the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02311418A (en) * 1989-05-26 1990-12-27 Terumo Corp Pharmaceutical for hemodialysis and its production
EP0602921A1 (en) * 1992-12-14 1994-06-22 Tomita Pharmaceutical Corporation Limited Bicarbonate dialysis dialysate component and method of manufacture
JPH06335527A (en) * 1993-04-02 1994-12-06 Morishita Roussel Kk Sodium bicarbonate dialysis pharmaceutical
JPH0892071A (en) * 1994-09-27 1996-04-09 Morishita Roussel Kk Bicarbonate dialyzing agent
JPH0892070A (en) * 1994-09-27 1996-04-09 Morishita Roussel Kk Blood dialyzing agent
JPH11343230A (en) * 1998-05-27 1999-12-14 Nissho Corp Agent for solid sodium bicarbonate dialysis
JP2001149468A (en) * 1999-11-25 2001-06-05 Nissho Corp Solid sodium bicarbonate dialyzing agent and its preparation process
JP2002102337A (en) * 2000-09-27 2002-04-09 Nipro Corp Solid dialyzing pharmaceutical preparation and method of preparing for the same

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007131563A (en) * 2005-11-09 2007-05-31 Manac Inc Solid formulation for dialysis and method for producing the same
US9931453B2 (en) 2012-10-10 2018-04-03 Tomita Pharmaceutical Co., Ltd. Dialysis agent a containing acetic acid and acetate salt, and a two-part dialysis agent using thereof
US10251988B2 (en) 2012-10-10 2019-04-09 Tomita Pharmaceutical Co., Ltd. Dialysis agent a containing acetic acid and acetate salt, and a two-part dialysis agent using thereof
US10525078B2 (en) 2013-10-02 2020-01-07 Tomita Pharmaceutical Co., Ltd. Solid dialysis A agent containing alkali metal diacetate, and two-part type low-acetate dialysis agent using same
JP2016153391A (en) * 2015-02-16 2016-08-25 日本合成化学工業株式会社 Anhydrous sodium acetate crystal
CN113975292A (en) * 2021-12-28 2022-01-28 广州康盛生物科技股份有限公司 Preparation method of hemodialysis dry powder component A not prone to caking
CN113975292B (en) * 2021-12-28 2022-03-25 广州康盛生物科技股份有限公司 Preparation method of hemodialysis dry powder component A not prone to caking

Similar Documents

Publication Publication Date Title
EP2151247B1 (en) Solid dialysis preparation
WO2005074948A1 (en) Solid formulation for dialysis and process for producing the same
JPH06178802A (en) Production of agent for artificial kidney perfusion for bicarbonate dialysis and the agent
JP4603977B2 (en) Dialysis solid preparation and method for producing the same
JP2987488B2 (en) Solid dialysis agent and method for producing the same
JP3647898B2 (en) Sodium bicarbonate dialysis agent and method for producing the same
JP3530235B2 (en) Hemodialysis agent
WO2004066977A1 (en) Solid agent for dialysis and process for producing the same
JP4989876B2 (en) Dialysis solid preparation and method for producing the same
JP3415291B2 (en) Bicarbonate dialysis agent
JP5028122B2 (en) Single-agent dialysis solid preparation and method for producing the same
JP2005230361A (en) Solid agent for dialysis and manufacturing method therefor
JP4878233B2 (en) Dialysis solid preparation and method for producing the same
JP2809971B2 (en) Hemodialysis preparation
JP4561978B2 (en) Solid dialysis agent and method for producing the same
EP1086700B1 (en) A solid pharmaceutical composition for dialysate containing sodium bicarbonate and a process for producing the same
CA2259623A1 (en) Method for the production of a granulate for hemodialysis
JPH11343230A (en) Agent for solid sodium bicarbonate dialysis
JP2986256B2 (en) Granules for hemodialysis
JP4385802B2 (en) Method for producing powder dialysis agent
JP2005239618A (en) Method for producing powdery dialysis preparation
JP2003093502A (en) Solid dialysing agent and method for manufacturing the same
JP2007130165A (en) Odorless solid agent for dialysis and its manufacturing method
JPH02311419A (en) Pharmaceutical for hemodialysis and its production
JP2005194199A (en) Solid dialysis agent and method for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005504763

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20048031381

Country of ref document: CN

122 Ep: pct application non-entry in european phase